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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre    over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Etiology, epidemiology and impact. 
Foot and mouth disease (FMD) is the most contagious disease of mammals and has a great potential for causing 
severe economic losses in susceptible cloven-hoofed animals. 
Foot and mouth disease virus (FMDV) is a member of the genus Aphthovirus in the family Picornaviridae. The 
FMDV particle consists of the RNA genome surrounded by a protein shell or capsid. The FMDV capsid readily 
dissociates at mild acidic conditions and at room temperature.  There are seven serotypes of FMD virus: O, A, C, 
Asia-1, SAT-1, SAT-2 and SAT-3.  Within these serotypes, more than 65 strains have been recognized. Animals 
that have been infected by one FMDV do not necessarily have immunity to other strains. Infection provides little 
or no protection against other serotypes, although there are a few reports of apparent cross-protection in cattle, 
resulting in milder or asymptomatic infections. SAT strains are highly variable, with many topotypes, and are also 
less stable than other serotypes. 
FMD is typically an acute febrile illness with vesicles on the feet, in and around the mouth, and on the mammary 
gland. The vesicles usually rupture rapidly, becoming erosions. Pain and discomfort from the lesions leads to 
clinical signs such as anorexia, excessive salivation, lameness and reluctance to move or rise. In severe cases, the 
hooves or footpads may be sloughed. Reproductive losses are possible, particularly in sheep and goats. Deaths 
are uncommon except in young animals, which may die from multifocal myocarditis or starvation. Most adults 
recover in 2 to 3 weeks, although secondary infections may slow recovery. African buffalo often act as long term 
reservoir hosts for the SAT serotypes in Africa posing a challenge for FMD control in Southern Africa. 
FMDV can be found in all secretions and excretions from acutely infected animals, including expired air, saliva, 
milk, urine, faeces and semen, in the fluid from FMD-associated vesicles, and in amniotic fluid and aborted 
foetuses in sheep. Mechanical transmission by fomites and living vectors is important. Airborne transmission can 
occur under favourable climatic conditions.  There are FMD carriers, animals in which either viral nucleic acids or 
live virus can be found for more than 28 days after infection. Animals can become carriers whether or not they 
had clinical signs. The epidemiological significance of carrier animals is uncertain and controversial. 
Although a disease of low mortality, the global impact of FMD is colossal due to the huge numbers of animals 
affected.  The impact of the disease differs considerable in different parts of the world. It has been estimated 
that annual impact of FMD in terms of visible production losses and vaccination in endemic regions alone 
amount to between US$6.5 and 21 billion. In addition, outbreaks in FMD free countries and zones cause losses 
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Incidence / Prevalence 
FMD is endemic in parts of Asia, Africa and the Middle East. South America has made big progress in its control. 
While serotypes O and A are widely distributed, SAT viruses occur mainly in Africa (with periodic incursions into 
the Middle East) and Asia 1 is currently found only in Asia.  Many countries are free of FMD, including Indonesia 
and Madagascar within the countries of interest.  Despite the relevance of the disease, not many prevalence 
studies are available, and more recent studies focus on molecular surveys.  
 
Diagnosis 
Diagnosis of FMD is by virus isolation or by the demonstration of FMD viral antigen or nucleic acid in samples of 
tissue or fluid. Detection of virus-specific antibody can also be used for diagnosis, and antibodies to non-
structural proteins (NSPs) can be used as indicators of infection, irrespective of vaccination status. However, in 
order to use the DIVA (differentiate infected from vaccinated animals) tests, the vaccine should be purified to so 
they are free of immunogenic contaminating NSPs.  
 
Control 
Measures taken to control an outbreak include quarantines and movement restrictions, euthanasia of affected 
and exposed animals, and cleaning and disinfection of affected premises, equipment and vehicles. Additional 
actions may include euthanasia of animals at risk.  Vaccination may be used to reduce the spread of FMDV or 
protect specific animals during some outbreaks. The decision to use vaccination is complex, and varies with the 
scientific, economic, political and societal factors specific to the outbreak. Vaccines are also used in endemic 
regions to protect animals from illness. FMDV vaccines only protect animals from the serotype(s) contained in 
the vaccine. Experimentally, interferon has been evaluated to stop the disease while the immunity elicited by 
vaccination develops.  
Import regulations help prevent FMDV from being introduced into free areas. Global FMD control programs 
have been established by FAO and OIE to reduce virus circulation and the incidence of this disease. The FMD 
Progression Control Pathway supported under the global program, has been adopted by many countries.  
 
Current vaccines and recent developments 
Currently, a number of commercially manufactured vaccines are available of differing strain composition, 
antigenic content (can be monovalent or polyvalent), adjuvant formulation and cost. All are produced using 
inactivated antigens. Duration of immunity is 4-6 months. Inactivated FMD vaccines are unable to induce sterile 
immunity, and viral replication may happen in the epithelial surface of vaccinated animals, resulting in a carrier 
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state of FMDV. FMD vaccine is a high-cost product since it must be produced within biosecure facilities.  Only 
purified vaccines have DIVA capability, but they are more expensive to produce.  
FMD vaccines may be classified as either ‘standard’ or ‘higher’ potency vaccines. Standard potency vaccines 
contain sufficient antigen to ensure that they meet the minimum potency level required. This vaccine is usually 
suitable for routine vaccination campaigns.  To control FMD outbreaks in naïve populations, higher potency 
vaccines are recommended for their wider spectrum of immunity as well as their rapid onset of protection.  
For cattle vaccines, aluminium hydroxide saponin adjuvanted and oil adjuvanted vaccines may be used. Double 
oil-emulsion vaccines are thought to provide a stronger and longer antibody response than water-in-oil single 
emulsion vaccines. Vaccines with oil adjuvants are reported to have a better shelf life. The aluminum hydroxide-
saponin formulated vaccines are easier to produce. For pigs, double oil emulsions are preferred due to their 
efficacy. Aluminum hydroxide vaccines are also less potent per microgram of antigen, and produce a shorter 
duration of immunity. Strain-related differences may affect vaccine manufacture and storage.  SAT viruses are 
less stable than other serotypes. There is one commercial vaccine combined with Haemorrhagic Septicaemia 
produced in India.  
For adequate protection, the vaccine strains must also be well matched with the field strain. The two important 
determinants are the ability of the vaccine strain to elicit antibodies that will cross-react and protect against the 
field or outbreak virus in question and the potency of the vaccine. The in vitro tests currently used for vaccine 
matching present some challenges.  Adaptation of field viruses to vaccine production requires adaptation of the 
virus to culture, and the whole process can take 6 months or more.  
Recent developments include the conditional licence in the USA of the replication defective hAd5-vectored 
vaccine developed by USDA, which Merial is now developing. It has many advantages, but concerns include that 
immune responses to the vector might limit the efficacy of the vaccine, the high dose required and the cost. 
USDA is working on a new generation of this vaccine, and OVI is working on its use for SAT serotypes.  
Commercial synthetic peptide vaccines have been in use in Asia for pigs for several years. They do not work in 
cattle. Communications from the field in Asia indicate that the vaccines produce good antibody titres, but they 
are not as effective as inactivated vaccines in preventing clinical signs.  
 
Research & potential new vaccine candidates  
There is a need for a better FMD vaccine, and vaccines better adapted to the SAT types.  There are many 
research and government organizations working on new or improved FMD vaccines. ARS-USDA and The Pirbright 
Institute seem to be leading the field and they have many international collaborations. The Global FMD Research 
Alliance (GFRA) brings together these organizations.  There are also private companies working on FMD, such as 
Harrisvaccines which has in the pipeline a vaccine based on an alphavirus replicon technology. Zoetis is working 
with USDA on a leaderless inactivated candidate (FMDLL3B3D), and MSD is working on VLP using a baculovirus 
expression system. Other commercial producers like Jinyu in China, are also working on improving FMD 
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vaccines. It is important to note research focused on SAT serotypes. OVI and collaborators have been working on 
chimeric vaccines, with cell culture adaptation phenotypes, as well as SAT and O viruses’ stability. These look like 
important candidates to consider for Africa. Research is focused in aspects such as improving stability, widening 
the scope of protection, easiness to introduce field strains, matching the field strains, quantification of the 
antigen content and integrity. Different strategies are being used including cDNA-derived inactivated vaccines, 
recombinant proteins, empty capsid vaccines, and DNA vaccines. For more details, see Section 8. 
 
Commercial manufacturers of FMD vaccines 
There are several FMD vaccine manufactures in Asia in Africa. Some of the African manufacturers need support 
on purification of the vaccine in order to get DIVA characteristics, but critical to them is technology transfer for 
QC, vaccine matching and technology that can facilitate the adaptation of field isolates, especially for SAT types.  
Similar needs are seen in some Asian manufactures.  AAHL, Australia has been helping some of the Asian 
countries, but would like to increase their support to other SEA countries, which due to animal movements, are 
the source of the outbreaks. PANVAC has also expressed the need to increase QC in African vaccines, and could 
benefit of a technology transfer such as that being carried out by AAHL. Methodologies such as the avidity ELISA 
developed by INTA for evaluation of cross-protection would be a great asset for many manufacturers.  
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Etiology & Epidemiology 
 
Foot and mouth disease (FMD) is the most contagious disease of mammals and has a great potential for causing 
severe economic losses in susceptible cloven-hoofed animals. 
Foot and mouth disease virus (FMDV) is a member of the genus Aphthovirus in the family Picornaviridae. As an 
RNA virus, FMDV has significant genetic variability. There are seven serotypes: O, A, C, Asia-1, SAT-1, SAT-2 and 
SAT-3 (Table 1).  Within these serotypes, more than 65 strains have been recognized. Older strains have names 
such as O1 Manisa or A24 Cruzeiro, but the names of recently isolated strains are more standardized and include 
the date and location of isolation (e.g., O/UK/35/2001). Some serotypes have been divided into topotypes, 
genetically and geographically distinct units that contain closely related strains of the virus. Asia-1 viruses have 
sometimes been classified into various “groups” or lineages [1].  
 
Table 1: Ten leading disease losses globally by livestock disease units (LSU) loss 
 
Serotype Topotypes Comments 
O 1. Middle East-South Asia (ME-SA) 




6. East Africa 
7. West Africa 
8. Europe-South America 
Most prevalent worldwide.  ME-SA is the 
dominant topotype, and contains the PanAsia 
lineage.  
Called O by Vallee and Carre who initially 
discovered it, for the department of Oise in 
France, where it originated [2] 
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A Several topotypes. Novel strains emerged and 
disappeared regularly in Asia and South America. 
Antigenically and genetically diverse.  
Called A for Allemagne (Germany in French) when 
first discovered by Valle and Carre.  
C  Uncommon. Last cases Brazil and Kenya 2004. 
Asia-1 Relatively stable Sometimes classified into “Groups” or lineages. 
SAT-1 Highly variable SAT: South African Territories 
SAT-2 Highly variable  
SAT-3 Highly variable Uncommon in domesticated animals.  
 
Overall, type O is usually the most prevalent and widely distributed serotype. Serotype O currently contains 
eight topotypes (see Table 1). Middle East- South Asia (ME-SA) is the dominant topotype, and contains the 
PanAsia lineage of FMDV. This lineage became prominent in India in the 1990s, spread into most of Asia, and has 
been responsible for a number of recent outbreaks in FMD-free countries throughout the world. In addition to 
causing the 2001 epizootic in the U.K., the PanAsia lineage affected Taiwan, Japan, South Africa, France, the 
Netherlands and South Korea in 2000-2002, and caused epizootics in a number of Middle Eastern countries in 
2007.  Serotype A is antigenically and genetically diverse, and also contains a number of topotypes. Antigenically 
novel strains of this serotype have emerged and disappeared regularly in Asia and South America. SAT strains 
are likewise highly variable. Asia-1 viruses have tended to remain relatively stable in their antigenic types, 
despite the occasional emergence of new strains. However, this serotype has recently caused a number of 
outbreaks throughout Asia, and appears to have spread rapidly, causing concern. New Asia-1 variants, which are 
poorly matched with the standard vaccine strain (Asia-1 Shamir) have been recognized during these outbreaks. 
Some FMDV serotypes are rarely seen. SAT 3 is uncommon in domesticated animals (although it can be found in 
wildlife in Africa), and the last known cases caused by serotype C occurred in Brazil and Kenya in 2004. 
Types O, A, SAT-1, SAT-2 and SAT-3 are the serotypes usually reported from Africa, while serotypes O, A and 
Asia- 1 occur in Asia. FMD viruses frequently enter the Middle East from both Asia and Africa. Serotypes O, Asia-
1 and A are common in this region, and SAT-1 and SAT-2 viruses also make periodic incursions from Africa. In the 
long term, the SAT viruses seem able to persist only in Africa. Only serotypes O and A are usually detected in 
South America. Few outbreaks have been reported from this region in recent years. The predominant FMDV 
topotypes in a region sometimes remain stable for long periods. However, viruses can also spread into new 
areas, and new strains can develop spontaneously.  It may be difficult to predict the behaviour of a field strain of 
FMDV unless its epidemiology is already known from other epidemics and controlled experiments. 
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Based on genetic and antigenic analyses, FMDVs throughout the world have been sub-divided into seven 
regional pools: Eurasia, Eastern Asia, Southern Asia, Eastern Africa, Western Africa, Southern Africa and South 
America (Figure 1) which seem to maintain distinct groups of viruses. Certain countries share viruses belonging 
to two different pools, for example, Egypt and Libya. This tendency apparently reflects some degree of 
ecological isolation, likely reflecting patterns of animal movement and trade or specific wildlife reservoirs (e.g. 
African buffalo) within a region. Virus circulation and evolution within these regional virus pools result in 




Figure 1: Worldwide distribution of the different FMD serotypes.  
Source: Dr King presentation at GFRA Scientific meeting, Hanoi – Vietnam 2015.  
 
 
FAO FMD World Reference laboratory, The Pirbright Institute, produces 
quarterly reports with a summary of the samples received, virology results, 
sequence analysis, vaccine matching and vaccine strain recommendations:  
http://www.wrlfmd.org/ref_labs/fmd_ref_lab_reports.htm. As an example, 
for the latest report (October-December 2015), click on Figure 2.  
 
 
Figure 2: Worldwide distribution of the different FMD serotypes.  
Source: Dr King presentation at GFRA Scientific meeting, Hanoi – Vietnam 2015.  
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FMDV can infect most or all members of the order Artiodactyla (cloven-hooved mammals), as well as a few 
species in other orders. Livestock susceptible to FMD include cattle, pigs, sheep and goats, as well as Asian water 
buffalo. Llamas and alpacas can be infected experimentally, but they do not seem to be very susceptible, and 
natural infections do not appear to be common. Recent studies suggest that Bactrian camels can develop FMD, 
but dromedary camels have little or no susceptibility to this virus. FMDV is not known to infect horses, mules or 
donkeys.  At least 70 species of wild animals are variably susceptible to FMD. Most are members of the 
Artiodactyla and include African buffalo, giraffes, wildebeest, blackbuck, waterbuck, wild boar, kudu, impala and 
tapir. Non-cloven-hooved animals reported to be susceptible to natural and/or experimental infection include 
European and African hedgehogs, armadillos, kangaroos, nutrias, chinchillas, capybaras, mink, European moles, 
and voles. Laboratory animal models include guinea pigs, rats and mice, but these species are not important in 
transmitting FMDV in the field. 
Strains of FMDV can vary in their species preferences, clinical presentation, transmission characteristics and 
possibly their tendency to become established in carriers. While most strains affect all susceptible host species, 
some have a more restricted host range.  Cattle are usually the most important maintenance hosts for FMDV 
except in Africa, where African buffalo maintain SAT type viruses. There is also evidence that some FMDV 
isolates might circulate in populations of Asian water buffalo. Some viral strains may primarily be found in pigs, 
sheep or goats. The pig-adapted serotype O Cathay strain has not infected large ruminants in outbreaks. Some 
serotype O strains are well-adapted to sheep and goats, although they can also affect cattle. However, it is 
uncertain whether small ruminants can maintain FMDV for long periods if cattle are absent. African buffalo 
often act as long term reservoir hosts for the SAT serotypes in Africa; there are reports of FMDV maintained in a 
herd of African buffalo for at least 24 years. With the exception of African buffalo, there is currently no evidence 
that wildlife hosts maintain FMDV for more than a few months if domesticated livestock are not infected. 
 
Virus structure 
The FMDV particle is roughly spherical in shape and about 25–30 nm in diameter. It consists of the RNA genome 
surrounded by a protein shell or capsid [2]. The capsid is composed of 60 copies of the capsomers. Each 
capsomer consists of four structural polypeptides, VP1, VP2, VP3 and VP4. The VP1, VP2 and VP3 are exposed on 
the surface of the virus while VP4 is located internally. The FMDV capsid (146S particles) readily dissociates at 
mild acidic conditions and at room temperature into their constituent subunits (12S particles).  The protein coat 
surrounds a single stranded, positive sense RNA genome about 8400 nucleotides (nt) in length. The RNA includes 
three separate parts i.e. the 5′ untranslated region (5′ UTR), a long coding region and the 3′ untranslated region 
(3′ UTR) (Figure 3).  
The coding region is the major portion of the viral genome. It encodes a large polyprotein which is then cleaved 
by viral proteases to form four different structural and eleven different non-structural proteins plus a variety of 
precursors. After translation, initially four primary products are formed, Leader protease (Lpro), P1-2A, P2 and 
P3. The Lpro is responsible for the inhibition of host cell protein synthesis by inducing the cleavage of the host 
protein, eIF4G, which is a translation initiation factor that is required for the translation of the capped cellular 
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mRNAs. As a result, FMDV RNA can freely use the host cell’s protein synthesis machinery for its own protein 
synthesis. The P2 and P3 regions of the polyprotein are processed to the non-structural proteins (NSPs). The P2 
region generates the proteins 2B and 2C while the P3 region is cleaved to form the proteins 3A, three distinct 
copies of VPg (3B1-3), 3Cpro and 3Dpol. 
The nucleotide sequences of the VP1 coding region have been used for genetic characterization of FMDV strains 




Figure 3: Genome organization of the FMDV and the structure of the virus. Source: Jamal and Belsham, 
2013 [2] 
 
Serotypes and cross-protection 
Animals that have been infected by, or immunized against, one FMDV do not necessarily have immunity to other 
strains. Conventional inactivated vaccines do not protect animals against other serotypes of FMDV. An infection 
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also provides little or no protection against other serotypes, although there are a few reports of apparent cross-
protection in cattle, resulting in milder or asymptomatic infections. Possible explanations for these cases include 
immune responses to conserved epitopes recognized by CD8+ T cells and/or to conserved non-structural 
proteins. Within a serotype, protection between strains varies with their antigenic similarity.  
 
Transmission 
FMDV can be found in all secretions and excretions from acutely infected animals, including expired air, saliva, 
milk, urine, feces and semen, as well as in the fluid from FMD-associated vesicles, and in amniotic fluid and 
aborted fetuses in sheep. The amount of virus shed by each route can be influenced by the host species and viral 
strain. Pigs produce large amounts of aerosolized virus, and the presence of large herds of infected swine may 
increase the risk of airborne spread. Peak virus production usually occurs around the time vesicles rupture and 
most clinical signs appear. However, some animals can shed FMDV for up to four days before the onset of 
clinical signs. The virus can enter the body by inhalation, ingestion or through skin abrasions and mucous 
membranes. Susceptibility to each route of entry can differ between species. Cattle are particularly susceptible 
to aerosolized virus, while pigs require much higher doses to be infected by this route. Sexual transmission could 
be a significant route of spread for the SAT type viruses in African buffalo populations. In sheep, FMDV has been 
shown to cross the placenta and infect the fetus. 
Mechanical transmission by fomites and living vectors is important. Airborne transmission can occur under 
favorable climatic conditions, with some viruses potentially spreading long distances, particularly over water. 
There is limited information on the survival of FMDV in the environment, but most studies suggest that it 
remains viable, on average, for three months or less. FMDV is sensitive to pH, and it is inactivated at pH below 
6.0 or above 9.0. This virus can persist in meat and other animal products when the pH remains above 6.0, but it 
is inactivated by acidification of muscles during rigor mortis. Because acidification does not occur to this extent 
in the bones and glands, FMDV may persist in these tissues. People can act as mechanical vectors for FMDV, by 
carrying the virus on clothing or skin. 
FMDV carriers are defined as animals in which either viral nucleic acids or live virus can be found for more than 
28 days after infection. Animals can become carriers whether or not they had clinical signs. The epidemiological 
significance of livestock FMDV carriers is uncertain and controversial. The only successful experiments were 
those that involved African buffalo carrying SAT viruses, which transmitted the virus to other buffalo and 
sporadically to cattle.  How long an animal can remain a carrier varies with the species. Most cattle carry FMDV 
for six months or less, but some animals can remain persistently infected for up to 3.5 years. The virus or its 
nucleic acids have been found for up to 12 months in sheep (although most seem to be carriers for only 1 to 5 
months), up to 4 months in goats, for a year in water buffalo, and up to 8 months in yaks. Individual African 
buffalo can be carriers for at least five years, and the virus persisted in one herd of African buffalo for at least 24 
years. Many outbreaks in Southern and Eastern Africa are linked to buffaloes. Camelids do not seem to become 
carriers. Pigs are not thought to become carriers.   
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FMD is typically an acute febrile illness with vesicles (blisters) localized on the feet, in and around the mouth, 
and on the mammary gland. Vesicles occur occasionally at other locations including the vulva, prepuce, or 
pressure points on the legs and other sites. The vesicles usually rupture rapidly, becoming erosions. Pain and 
discomfort from the lesions leads to clinical signs such as depression, anorexia, excessive salivation, lameness 
and reluctance to move or rise. Lesions on the coronary band may cause growth arrest lines on the hoof. In 
severe cases, the hooves or footpads may be sloughed. Reproductive losses are possible, particularly in sheep 
and goats. Deaths are uncommon except in young animals, which may die from multifocal myocarditis or 
starvation. Most adults recover in 2 to 3 weeks, although secondary infections may slow recovery. Possible 
complications include temporary or permanent decreases in milk production, hoof malformations, chronic 
lameness or mastitis, weight loss and loss of condition. 
Both mouth and foot lesions can occur in water buffalo, but the clinical signs are reported to be milder than in 
cattle. Pigs, usually develop the most severe lesions on their feet. Mouth lesions are usually small and less 
apparent than in cattle. FMD tends to be mild in sheep and goats. A significant number of infected animals may 
be asymptomatic or have lesions only at one site. Common signs in small ruminants are fever and mild to severe 
lameness of one or more legs. Mouth lesions are often not noticeable and not severe, and generally appear as 
shallow erosions. Significant numbers of ewes abort in some outbreaks. Young lambs and kids may die due to 




Diagnosis of FMD is by virus isolation or by the demonstration of FMD viral antigen or nucleic acid in samples of 
tissue or fluid. Detection of virus-specific antibody can also be used for diagnosis, and antibodies to NSPs can be 
used as indicators of infection, irrespective of vaccination status. However, in order to use the DIVA 
(differentiate infected from vaccinated animals) tests, the vaccine should be purified to the extent that they 
should be free of immunogenic contaminating NSPs.  
In acutely infected animals, FMDV, its antigens or nucleic acids can be found in a variety of samples including 
vesicular fluid, epithelial tissue, nasal and oral secretions, esophageal-pharyngeal fluids, blood and milk, and in 
tissue samples such as myocardium collected at necropsy. Carrier animals can only be identified by collecting 
esophageal-pharyngeal fluids for virus isolation and/or the detection of nucleic acids.  
Serological tests can be used in surveillance, to certify animals for export, to confirm suspected cases during an 
outbreak, to monitor immunity from vaccination, and in matching vaccines to field strains. Test cutoff values can 
differ with the purpose of the test. Some serological tests detect antibodies to the viral structural (e.g., capsid) 
proteins. They include ELISAs and virus neutralization tests, and are serotype specific. Because FMDV vaccines 
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also induce antibodies to structural proteins, these tests can only be used in unvaccinated animals. Other 
serological tests (e.g., some ELISAs and the enzyme-linked immuno-electrotransfer blot) detect antibodies to 
FMDV non-structural proteins (NSPs), which are expressed only during virus replication. NSP tests are not 
serotype specific, and can be used in both vaccinated and unvaccinated animals. However, they are less 
sensitive and may not detect cases with limited virus replication, including some vaccinated animals that 
become infected. Due to such limitations, serological tests that detect antibodies to NSPs are generally used as 
herd tests. 
• OIE recognized tests: 
a) Identification of the agent: virus isolation, enzyme-linked immunosorbent assays (ELISAs), 
Lateral flow devices, Complement Fixation Test, nucleic acid recognition methods such as 
reverse transcription polymerase chain reaction (RT-PCR). 
b) Serological tests: Virus neutralization, solid-phase competition ELISA, liquid-phase blocking 
ELISA. 
NSP antibody tests can be measured by different ELISA formats or immunoblotting. 
• Differential diagnosis: 
Vesicular stomatitis, swine vesicular disease and vesicular exanthema of pigs all produce lesions in cattle or pigs 
which are clinically indistinguishable from FMD. Conditions which produce erosions or ulceration in the mouth 
or on the muzzle of livestock, include bovine virus diarrhoea/mucosal disease, bluetongue, malignant catarrhal 
fever, lumpy skin disease, papular stomatitis, infectious bovine rhinotracheitis and orf (contagious pustular 
dermatitis). None of these diseases, except bluetongue and occasionally orf, usually produce foot lesions.   
 
Immunity 
Humoral immune responses, with the production of neutralizing antibodies, are generally correlated with 
recovery from infection with FMDV and resistance to reinfection. Cell-mediated immune responses (CMI) have 
also been reported in FMDV infected animals, although the role of this form of immunity is still under 
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Foot and mouth disease is endemic in parts of Asia, Africa, the Middle East and South America. While serotypes 
O and A are widely distributed, SAT viruses occur mainly in Africa (with periodic incursions into the Middle East) 
and Asia 1 is currently found only in Asia. See Table 1 and Figure 2.  
North and Central America, New Zealand, Australia, Greenland, Iceland and western Europe are free of FMDV. 
Western Europe was affected by some recent outbreaks (eradication was successful), but FMD has not been 
reported in North America for more than 60 years. Parts of South America have successfully eliminated FMD 
with the use of the inactivated vaccine.   
FMD is the first disease for which the OIE established an official list of free countries and zones. The OIE has 
defined a transparent, science-based and impartial procedure for the recognition of FMD disease status of 
Member Countries and Territories in their entirety or defined zones. Categories for FMD disease status include 
FMD free without using vaccination and FMD free with use of vaccination. The latest official status can be seen 
in Figure 4 below.  A detailed list of the countries is included in the following link: http://www.oie.int/animal-
health-in-the-world/official-disease-status/fmd/list-of-fmd-free-members/   
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Figure 4: OIE Member Countries’ official FMD status map, updated May 2015.  
Source: OIE http://www.oie.int/en/animal-health-in-the-world/official-disease-status/fmd/en-fmd-carte/  
 
Incidence FMD data by country 
There are two main sources, OIE and AU-IBAR (which includes only Africa), but data are not always similar.   
 
1- Source: OIE.   
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 2 and 3.  Data are 
not always reliable, as many countries doesn’t seem to report, or to be reporting consistently over time.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
Similar information but presented in a different manner can be seen in Annex 2.   
 
Number of cases reported to the OIE by disease and by country: 
     -   No information,      +   Present but quantitative data not known,   ?  Disease suspected 
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Table 2: Ten leading disease losses globally by livestock disease units (LSU) loss 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - + + + + + + + + - 
India 2,270 1,646 1,547 449 902 422 701 879 377 238 - 
Indonesia* 0 0 - 0 0 0 0 0 0 - - 
Myanmar + >34 17 11 21 10 7 3 9 4 - 
Nepal 252 24 >9 >2 204 22 72 41 66 43 36 




Table 3: AFRICA – FMD outbreaks notified to OIE from the Asian countries of interest.  
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso 66 27 89 89 45 111 161 69 37 193 >28 
Ethiopia 24 >8 22 18 >34 67 85 167 63 21 - 
Ivory Coast >4 0 ? 4 >6 15 13 5 4 5 11 
Kenya 31 42 39 43 62 >61 60 144 42 173 >81 
Madagascar* 0 0 0 0 0 0 0 0 0 0 - 
Malawi - - - >4 >1 + 2 0 0 - - 
Mali 22 24 9 11 0 4 3 0 1 6 0 
Mozambique 0 0 0 0 0 10 1 0 0 6 - 
Rwanda - 5 >6 >1 >4 >7 ? >23 10 - - 
Senegal 2 46 7 84 42 6 12 15 0 3 5 
South Africa 0 2 0 3 4 6 48 5 >13 4 - 
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Tanzania 34 36 57 27 23 51 14 30 22 18 25 
Uganda 5 13 >2 32 >2 4 20 7 6 15 - 
Zambia - +? + 9 19 1 0 2 0 0 - 
 
* Madagascar is recognised FMD free by the OIE.  
 
2- Source: AU-IBAR. 
The African Union Inter-African Bureau for Animal Resources also has a notification system. Data are published 
in the Pan African Animal Resources Year Books. (http://www.au-ibar.org/pan-african-animal-resources-
yearbook?showall=&limitstart=). Similarly to the OIE, many countries do not seem to consistently report the 
outbreaks.  
Note that the number of outbreaks reported often does not match those reported to the OIE. 
 
Table 4: Number of FMD outbreaks per year as reported to AU-IBAR and published in the Pan African 
Animal Resources YearBook.  NS= Not specified  
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso 66 20 420 90 40 111 164 69 36 194  
Ethiopia 12  26 56 13 95 87 158 113 7  
Ivory Coast 3   9 6 8 13 10 1 5  
Kenya   140 2 1 NS 28 11 6 48  
Madagascar            
Malawi    1 1  2     
Mali 2   1  4 2   7  
Mozambique      1 5     
Rwanda    6 3 1  1 1   
Senegal  50 7 66 43 6 13 20 7 4  
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South Africa  2  12 8 6 69 16 33 5  
Tanzania 22 49 73 0* NS NS 11 18 13 14  
Uganda 5 5 4  2  14 3 13 8  
Zambia    0* 1 NS 1  1   
 




Prevalence FMD data by country (from 2000 onwards) 
• Sources: PubMed, and internet engine searches (English and French when applicable).   
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference.  
• For grey literature, links have been included when possible.   
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted.  
• Prevalence data is quite limited for some countries, but details on incidence have been found, and they have 




Year Area Species of 
animal  
No. of outbreaks 








 Mondal & 
Yamage, 2014 
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Rajshaji Cattle: 347  25.07% Sarker et al, 2011 
2010 Nationwide 
surveillance program 









Upazila Vet Hospital, 
Meghna, Comilla 





Year Area Species of 
animal 
No. of outbreaks 








 Sheep: 20.35% 
Goats: 13.60% 
Rout et al, 2014 
2010 Orissa Goats  NSP-Ab: 38% 
SP-Ab: 20.7% 
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Central region: 5% 
Western region: 4.4% 
Northern region: 4%. 
1977-
2013 




 Hegde et al, 2014 
 
FMD outbreaks recorded in different regions of India and serotypes involved 2006-2011. 
Source: Subramaniam et al, 2013 
 
Indonesia 
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Year Area Species of 
animal 
No. of outbreaks 
(O), No. of cases (C)  
Prevalence Reference 
2010 Sagaing & 
Tanintharyi 
  Sagaing: 42% 
Tanintharyi: 11.7% 




Year Area Species of 
animal 
No. of outbreaks (O), No. of cases (C)  Reference 
2000-
2009 
 Various Outbreaks by species: 
Cattle: 42%         Buffalo: 32% 
Goats: 19%         Sheep: 4% 
Pigs: 3% 
For the number of outbreaks, see Figure 5 
below. 
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Year Area Species of 
animal 
No. of outbreaks 
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For details on the epidemiology of FMD in Africa, see Annex 1.  
 
West Africa 
In a study conducted in 2006 [3], including three cattle exporting Sahel countries (Burkina-Faso, Mali and Niger) 
and four cattle importing coastal countries (Benin, Côte d’Ivoire, Ghana and Togo), some FMD risk areas were 
identified, due to the high density of livestock (see Figure 6): 
1. Ivory Coast: North and Central regions 
2. Mali: Sikasso, Bamako, Ségou, Mopti, and Asango regions, and the border between Mali-Niger-Burkina-Faso. 
3. Burkina-Faso: all the country 
4. Niger: Border with Nigéria, Mali, Chad, cure salée región 
5. Bénin: Borgou, Atacora and Zou regions 
6. Togo: Coastal region, maritime, plateaux, and savanes (border with Burkina-Faso), 




Figure 6:  Risk areas for FMD corresponding to areas of high animal density. 
Source: Couacy-Hymann et al, 2006 [3] 
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Commercial and transhumance routes, play a very important role in the diffusion of the disease.  Some primary 
disease focus are:  the Benin – Niger – Nigeria border, the Niger – Mali – Burkina Faso border, and the junction 




Figure 7: Areas of primary disease. Source: Couacy-Hymann et al, 2006 [3] 
 
Burkina Faso 
No data on prevalence was found. However, Burkina Faso is considered a region at risk.  
 
Ethiopia 
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2014 Dassenech (South 
Omo zone) 
Cattle 68 10 Molla & Delil 
2015 
2011 Borana pastoral area Cattle 768 from 111 
herds 
Individual: 23 Bayissa et al, 
2011 
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South Omo zone Cattle 770 8.18 (3ABC ELISA) Molla et al, 2010 
2008-
2009 
East and West 
Hararghe zones in 
Oromiya state 








Southern Ethiopia Cattle 1,020 in 79 herds Individual: 9.5 
Herd: 48.1 




Whole country Cattle 4,465 10.5 (3ABC ELISA) 
For details see table below 
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Seroprevalence of FMD in different zones of Ethiopia, based on the 3ABC ELISA.  Source: Ayelet et al, 2012 
 
Ivory Coast 
No recent information was found.  
 
Kenya 
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2010 39 counties Cattle 3,709 52.5 Kibore et al, 2013 
2010 15 counties PIgs 180 NSP: 54.4 (NSP) Kibore et al, 2014 
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2010 Countrywide Pigs 191 NSP: 53% Wekesa et al, 2014 
 
Madagascar 
Recognized as FMD free by the OIE.  
 
Malawi, Mali, Mozambique, Rwanda and Senegal 
No recent data on FMD prevalence was found for any of those countries.  
 
South Africa 
South Africa is recognized by the OIE, as having a FMD free zone where vaccination is not practiced (see Section 
5). That covers the majority of the country.  The Infected zone is mainly the Kruger National Park.  
  
Tanzania 




% positive Reference 





330 76.3 (3ABC NSP) 
See details in table below. 
Mkama et al, 2014 
2014 Serengeti 
ecosystem, Central 









71.5. Non interface area: 61 
 
Kongwa: 89%, Serengeti: 78%, 
Bunda: 65% and Iramba 33%.  
 
Cattle: 69.81%, Sheep: 52.38% 
and goats: 11.11%. 
Mdetele and 
Kassanga, 2014 
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6 districts in Eastern 
Tanzania 
Cattle 91 Overall: 43.6 (NSP 3ABC) 
Bagamoyo: 81,  Kibaha: 56.2 
Kinondoni: 41.7, Ilala: 34.8 




FMD seroprevalence in cattle and buffaloes. Source: Mkama et al, 2014 
 
Uganda 
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2014 Isingiro and Nakasongola Cattle 17 herds 23.6 Baluka et al, 2014 
2011 Pastoral herds that closely 
interact with wildlife 
around Queen Elizabeth 
National Park 
Cattle  247 15 Dhikusooka et al, 
2016 




Cattle: K193, B: 
116 
Goats: K: 143, 
B:128 
Sheep: K: 57, B: 18  
Cattle: K: 61, B: 4 
Goats: K: 14, B: 0 
Sheep: K: 21, B: 0 









Ayebazibwe et al, 
2010 
Foot and Mouth Disease | Monograph 18 







Common eland: 1 
Waterbucks: 5 
The other 








% positive Reference 
2011-
2012 
National Parks & Game 
management areas 
Buffaloes 99 92.9 See table below for 
details 
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Economic and Social Impacts at Global 







Although a disease of low mortality, the global impact of FMD is colossal due to the huge numbers of animals 
affected.  The impact of the disease differs considerable in different parts of the world. In the developed world it 
is the most feared of all animal diseases with the possible exception of those that have zoonotic potential such 
as BSE. The reason is the devastating economic consequences it can have.   
The Taiwan case: Between March and July 1997, FMD struck Taiwan for the first time in sixty years. The 
particular strain of the virus was “pig-adapted”. The disease, which apparently originated on the Chinese 
mainland, spread like wildfire throughout Taiwan. Over a period of six weeks, FMD virus infected a total of 6,147 
pig farms, decimating the country’s huge swine industry. The price of Taiwanese pigs dropped 60 percent within 
a week, and the export market to Japan collapsed. Bringing the epidemic under control required the slaughter of 
some 4 million pigs at a cost of more than USD 6 billion, and some 50,000 workers in the swine industry lost 
their jobs. The Taiwanese swine industry never recovered. Before the 1997 outbreak, Taiwan was one the 
world’s leading pork exporters, but today it is a net importer. 
http://fas.org/biosecurity/education/dualuse-agriculture/1.-agroterrorism-and-foodsafety/economic-impact-
of-fmd-outbreaks.html 
The UK case: FMD struck the United Kingdom in 2001 after pigs were fed food scraps that were infected with 
the virus from a restaurant. The contaminated meat had either been smuggled into Britain or mislabelled with a 
false certificate of origin. Because the strain of FMD virus sickened pigs but did not cause obvious illness in other 
susceptible animals, sheep incubating the disease were distributed widely. By the time the outbreak was 
detected, between 30 and 50 farms throughout Britain had been affected, and the veterinary authorities were 
quickly overwhelmed. It took six months to contain the outbreak. Efforts by the British authorities to prevent the 
spread of the disease led to the culling of 6 million animals—4.9 million sheep, 700,000 cattle, and 400,000 pigs. 
The slaughter of vast numbers of animals (up to 100,000 per day) cost farmers a total of £3.1 billion and caused 
severe emotional distress. The British government paid £2.5 billion in compensation and for disposal and clean-
up costs. Because of reduced tourism and trade, the total cost to the British economy was more than £8 billion 
(USD 15 billion) 
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The impact of FMD in endemic countries is more controversial. In many pastoral communities in sub-Saharan 
Africa where the disease is prevalent and well recognized by livestock owners they often (although not always) 
ascribe little importance to it. The simple reason is that in extensive production systems dependent on 
“unimproved” livestock, the disease is usually relatively trivial and the animals recover uneventfully in a week or 
two. The loss of production in such systems is usually seen as unremarkable, although the disease may result in 
a lack of draught power for ploughing at critical times and therefore results in agricultural and social disruption.  
It may also affect production by the growing peri-urban, small-scale diaries developing in many parts of Africa.  
The lower impact of the disease in SSA may also, to some extent, be due to indigenous cattle having greater 
inherent resistance than breeds selected in developed countries for high yields. It has been said that in some 
endemic countries, for small livestock keepers, the control measures are more onerous than the disease itself 
(for example restrictions in taking their animals to market) but that is influenced by the unappreciated 
production losses.  
Knight-Jones and Rushton in their publication in 2013 [4], estimated that annual impact of FMD in terms of visible 
production losses and vaccination in endemic regions alone amount to between US$6.5 and 21 billion. In 
addition, outbreaks in FMD free countries and zones cause losses of >US$1.5 billion a year. 
This impact can be separated into two components: [1] direct losses due to reduced production and changes in 
herd structure; and [2] indirect losses caused by costs of FMD control, poor access to markets and limited use of 




Figure 8: The impact of FMD.  Source: Knight-Jones and Rushton, 2013 [4]. 
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The visible losses are more prominent in pigs and dairy cattle. They include reduced milk production (which can 
account for 33% of losses in endemic settings), suppressed growth rates, mortality in young animals (can be 2-
3%), loss of traction power, and abortions.  The invisible losses are mainly due to abortions and reduced 
conception rates.  
 
Indirect Cots 
Control costs: They vary depending on the measures taken by the veterinary services. Additional costs are taken 
by the private sector (for example vaccination). It is estimated that 2.35 billion doses of vaccine are administered 
in the world every year (Table 5).  
 





FMD impacts are not the same throughout the world [4]: 
1. FMD production losses have a big impact on the world’s poorest where more people are directly 
dependent on livestock. FMD reduces herd fertility leading to less efficient herd structures and 
discourages the use of FMD susceptible, high productivity breeds. Overall the direct losses limit livestock 
productivity affecting food security 
2. In countries with ongoing control programs, FMD control and management creates large costs. These 
control programs are often difficult to discontinue due to risks of new FMD incursion. 
3. The presence, or even threat, of FMD prevents access to lucrative international markets. 
4. In FMD free countries outbreaks occur periodically and the costs involved in regaining free status have 
been enormous. 
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FMD is highly contagious and the actions of one farmer affect the risk of FMD occurring on other holdings; thus 
sizeable externalities are generated. Control therefore requires coordination within and between countries. 
These externalities imply that FMD control produces a significant amount of public goods, justifying the need for 
national and international public investment. 
The global FMD impact due to vaccination cost and direct visible production losses can be seen in Table 6. The 
costs were estimated using variable reported vaccination costs, production losses and uncertain FMD incidence. 
The variation in total impact is shown (90% range) as well as median estimates. Vaccination costs of between 
US$0.4 and 3 (most likely US$1) per dose and production losses of between US$100 and 370 (most likely 
US$100) were used [4]. 
 
Table 6: Global FMD impact due to vaccination costs and direct, visible production losses by region. 







Individual country information 
For some of the focus countries, information on the impact of FMD is available:  
 
Bangladesh 
Momtaz et al 2014, mention that FMD is endemic in Bangladesh, and causes an annual economic loss of USD 60-
150 million in Bangladesh.  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219755/pdf/ebo-10-2014-187.pdf  
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Govindraj et al, 2015, conducted a study to assess the impact of FMD outbreaks in cattle and buffaloes on 
farming community in Kolar district, Karnataka state, India. Primary data were collected from 178 sample farms. 
The results showed that 78% of surveyed villages were affected with FMD.  
In indigenous cattle, the highest loss due to FMD was distress sale (208 USD) followed by other losses, whereas, 
in crossbred cattle, the highest loss was mortality loss (515 USD) followed by distress sale (490 USD), milk yield 
loss (327 USD), treatment cost (38 USD) and extra labour engagement expenses for nursing of FMD-affected 
bovines (30 USD) – all costs are per animal.  
In local and upgraded cattle, the mean total loss per affected animal was 521 USD and 1941 USD, respectively. In 
local and upgraded buffaloes, the mean total loss per animal was 639 USD and 1008 USD, respectively.  Table 7 
below shows the average losses due to milk yield reduction, draught power, treatment, mortality and distress 
sale for FMD-affected animals in Karnataka (USD/animal). 
As per the social impact, the majority of the livestock owners perceived FMD had caused permanent asset loss, 
which in turn increased psychological stress of the family.  
In a presentation by Ganesh Kumar, Project Directorate on Animal Disease Monitoring and Surveillance 
Bangalore (year not stated, but probably around 2010-2011) he explained that the total direct impact of FMD in 
farms in areas where there was a control program was R 41,482 (USD 892), and in farms with no control 
program was Rs. 63,768 (USD 1,372).  Indirect losses were not quantified.  It was also projected that the state of 
Andhra Pradesh would stand to lose Rs. 1,147 crores (Rs. 11,470 million, approx. USD 247 million) on account of 
direct impacts, if there was no vaccination programme against FMD. Similarly, the country would incur a total 
direct loss of Rs. 15,575 crores (155,750 million, approx. USD 3,351 million). The indirect costs would be much 
more than this. 
http://www.fao.org/docs/eims/upload/299846/an367e00.pdf  
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Table 7: Average losses due to milk yield reduction, draught power, treatment, mortality and distress sale 






Economic losses due to FMD infection in Nepal, have been estimated to be about USD 5.36 million per year. A 
study of the economic impact of livestock diseases in rural areas of Nepal estimated that FMD could account for 
26% of the overall economic losses in livestock production.  (Quoted by Chhetri et al, 2010).  
 
Ethiopia 
Jemberu et al, 2014, assessed the impact of FMD in Ethiopia based on data obtained from case outbreaks in 
cattle in crop-livestock mixed and pastoral smallholder farming systems that occurred in 2012 and 2013. FMD 
morbidity rates of 85.2% and 94.9% at herd level; and 74.3% and 60.8% at animal level in the affected herds 
were determined for crop-livestock mixed system and pastoral system, respectively. The overall and calf specific 
mortality rates were 2.4% and 9.7% for the crop-livestock mixed system, and 0.7% and 2.6% for the pastoral 
system, respectively. Herd level morbidity rate was statistically significantly higher in the pastoral system than in 
the crop-livestock mixed system (P<0.001). The economic losses of and FMD outbreak due to milk loss, draft 
power loss and mortality were on average USD 76 per affected herd and USD 9.8 per head of cattle in the 
affected herds in crop-livestock mixed system; and USD 174 per affected herd and USD 5.3 per head of cattle in 
the affected herds in the pastoral system. The herd level economic losses were statistically significantly higher 
for the pastoral system than for the crop-livestock mixed system (P<0.001). The major loss due to the disease 
occurred as a result of milk losses and draft power losses whereas mortality losses were relatively low. Although 
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the presented estimates on the economic losses accounted only for the visible direct impacts of the disease on 
herd level, these conservative estimates signify a potential socioeconomic gain from a control intervention. 
Knight-Jones and Rushton 2013, estimated the impact of FMD in different epidemiological and trade situations. 
As example of an endemic country with the potential to export, they presented Ethiopia: 
Ethiopia has the largest cattle population in Africa; in 2006 there were >43 million cattle with slightly fewer 
sheep and goats. Large numbers of ruminants are exported; in the Ethiopian financial year (July 2010–July 2011), 
meat and livestock export revenue was $211.1 million, mostly from live animal trade with the Middle East 
(>472,041 heads of live animals,70% of which were cattle). However, production costs are high compared to 
other meat exporting nations, such as Australia or Brazil, limiting the potential for export market access 
regardless of FMD status. Difficulties in meeting export Sanitary and Phyto-Sanitary standards results in greater 
numbers of livestock being purchased by traders for export through unofficial channels where prices are lower. 
Due to the presence of FMD and other OIE listed trade limiting diseases the export of live cattle and their 
products to FMD free countries is an unlikely prospect. This raises the case for investment in veterinary service 
infrastructure to improve the control of all trade limiting diseases for international market access. Having an 
economy that is highly dependent on smallholder and animal-based agriculture, including the widespread use of 
beasts of burden, the direct impacts of FMD are substantial in Ethiopia. In agro-pastoral areas, FMD infected 
oxen are unable to work for the entire season when affected at cropping time. Pastoralists are particularly 
vulnerable to FMD as their living depends entirely on their livestock. By reducing the supply of milk FMD impacts 
on food security, particularly when outbreaks occur during times of the year when other food sources are 
limited and dependency upon milk is greatest. 
 
Kenya 
Lyons et al 2015, used individual animal data from a large-scale dairy farm in Kenya to estimate the impact of an 
FMD outbreak due to serotype SAT2 virus on milk yield in an endemic setting. Daily milk yields from 218 mainly 
European-breed cattle that were lactating during the 29-day outbreak period were considered in the analysis. At 
the herd level, the average daily yields decreased from around 20 to 13kg per cow, recovering approximately 2 
months after the commencement of the outbreak. No difference was found between reported clinical and non-
clinical cases suggesting inaccurate case recording, poor sensitivity of the case definition and subclinical 
infections being present. To further investigate the impact of FMD, yields were predicted for each individual 
animal based on historic data from the same herd. For cattle lactating during the outbreak, comparisons were 
made between actual and predicted yields from the commencement of the outbreak to 305 days lactation using 
a linear regression model. Animals produced significantly less than predicted if in parity 2 or greater and 
between 0 and 50 days in milk (DIM) at the start of the outbreak period. The maximum effect was seen among 
animals in parity ≥4 and between 0 and 50 DIM at the start of the outbreak, producing on average 688.7kg 
(95%CI 395.5, 981.8) less milk than predicted for their remaining lactation, representing an average 15% 
reduction in the 305 day production for these animals. Generalisation of the results requires caution as the 
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majority of Kenyan milk is produced in smallholder farms. However, such farms use similar genetics and feeding 
practices to the study farm, and such systems are increasingly important in the supply of milk globally.  
In another paper, also Lyons et al 2015, reported the impact of an FMD (virus serotype SAT2) outbreak on a 
large-scale dairy farm in Nakuru County, on clinical mastitis and culling rate (presumably, the same farm as 
above). A cohort approach followed animals over a 12-month period after the commencement of the outbreak. 
Univariable analysis showed FMD cases were culled sooner but there was no effect on clinical mastitis. After 
adjusting for possible confounders and inclusion of time-varying effects there was weak evidence to support an 
effect of FMD on culling (HR = 1.7, 95% confidence intervals [CI] 0.88-3.1, P = 0.12). For mastitis, there was 




In Mali, the losses due to FMD (milk, meat, draught, cost of treatment) have been calculated to USD 600,000 per 





Baluka et al 2014, looked at the economic important of FMD in Isingiro district. They estimated the financial 
losses and economic costs associated to FMD in 17 herds.  Three, nine and five herds were selected to represent 
small (10-50 heads of cattle), medium (51-150) and large herds (151-350 heads of cattle) respectively.  The table 
below shows the annual economic cost of FMD in USD.  
During FMD outbreaks and associated quarantine period, more farmers with small and medium herds made 
losses because they were compelled to sell cattle at salvage sale prices due to lack of alternative sources of 
income for paying for drugs and vaccination or made distress sales in fear of losing the remaining cattle. Farmers 
with large herds neither incurred salvage nor mortality losses. Farmers with large herds experienced lower 
prevalence probably because they have alternative sources of income and can afford to pay for vaccination and 
buy drugs without having to sell their cattle at salvage prices. 
Large herds suffered higher milk losses during FMD outbreaks due to reduction of milk production, sale loss due 
to no sales and milk sale loss due to quarantine than either the small or medium herds. This is probably because 
many farmers with large herds have improved their breeds for milk production and in the absence of FMD, large 
herds sell more milk and earn more income from sale of milk than either small or medium herds. 
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Sinkala et al 2014 [6], looked at the impact of FMD on the Zambian economy, based on Knight-Jones and Rushton 
framework [4]. Impacts include losses in income of over US$ 1.6 billion from exports of beef and sable antelopes 
and an annual cost of over US$ 2.7 million on preventive measures: 
Direct visible losses:  During the 2004 Kafue flats Namwala outbreak, the calving rate reduced during the calving 
season as most cows did not conceive (Musso Munyeme, personal communication). Herdsmen had earlier 
observed that the bulls were failing to mount the cows during heat periods because of sores on the feet. On 
average around 300,000 calves are born every year in this region. During the 2008 outbreak of FMD at a 
commercial farm in Mazabuka district, milk production was reported to have dropped from 25.5 to 0.5 litres per 
cow per day (Martin Ndhlovu, personal communication). In Zambia, traditional farming using draught power 
accounts for the largest production of crops. Elsewhere oxen have been observed to stay off plough for the 
whole season when outbreaks occur in a cropping season with drop in draught power of 60–70% after one 
month following infection. 
Direct invisible losses: Low conception rates of 52 to 69%, calving rates averaging 40 to 58%, and long calving to 
conception intervals of 18 to 20 months characterize the reproductive efficiency in Zambia. This may be a result 
of endemic FMD infections. Fertility reduces because of increase in abortion rates of up to 10% and prolonged 
inter-calving interval by 12 months due to delays in conception. 
Indirect impacts: It is estimated that the Zambian Government spends over US$ 2.7 million yearly on procuring 
vaccines and conducting and monitoring vaccination campaigns. Biannual vaccination campaigns conducted 
each year consume the productive time of both the farmer and the field extensive officers to invest in other 
productive activities. With respect to government cost of control, it is estimated that the cost of erecting and 
maintaining one checkpoint during the 2004 Namwala outbreak was US$ 10,000 for two weeks. This figure may 
rise if the period is longer and sometimes three or more checkpoints were required. The cost of surveillance, 
extension, and farmer training in disease identification and awareness adds to expenditure. 
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Internal market constraints: In Zambia, demand for beef is the highest in Lusaka with a human population of 
2,196,996 and the Copper belt with 1,958,623. During disease outbreaks, movement restrictions imposed on 
livestock from affected regions create a deficit that leads to upswing of prices of beef and competing goods. 
Zambia currently imports beef to satisfy local market demand and any drop in the local source worsens the 
situation. Another consequence of being a country with endemic FMD is that Zambia cannot participate in 
international livestock trade. For example, as a result of the 2010 Mbala serotype O outbreak, Botswana 
imposed a total ban on import of maize bran from Zambia. Zambia exports in excess of 30,000 metric tons of 
maize bran annually to Botswana. It is further estimated that over US$ 3 Million was lost in revenue during the 
ban (George Phiri, Grain Traders Association, personal communication). In 2008, over 500 sable antelopes could 
not be exported to South Africa because of trade politics related to FMD. Losses in income from exports of these 
prime sable antelopes have been estimated at US$ 35 million annually. The loss in income from potential 
exports of beef and dairy products if a disease free zone existed has been estimated to be over US$ 1.6 billion 
per annum. 
Effect on the internal economic growth: The period between 2000 and 2010 was characterised by increase in the 
numbers of FMD outbreaks in comparison to previous decades. During the same period, the Zambian human 
population was increasing at an average of 2.8% per annum. The cattle decline experienced in the early 2000s 
was probably due to droughts and eventual FMD outbreaks on the Kafue flats. The reduction in calving and 
conception rates alluded to earlier may have contributed. Even though the country recorded an upswing in 
cattle numbers from 2,381,421 in 2005 to 2,559, 953 in 2010, the growth was not commensurate with the 
human population growth. Probably the extension of the 2004 Namwala outbreak to 2005 and 2006 as well as 
the 2007 to 2009 Mwandi outbreak in the middle Zambezi basin may have contributed. Zambia also experienced 
positive economic growth in real GDP from 2000 to 2010, but the economic growth was slow to support the 
population growth. This was mainly because the growth was driven by improved performance in mining and 
construction sectors while agriculture upon which 80% of the population depends did not perform well, 
recording relatively low average growth rates, inadequate infrastructure, and poor market access. 
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FMD is a highly contagious viral disease. It has been eradicated in many countries, and in those countries control 
is based in preventing the disease (re)entering the country.  In endemic regions, control will vary depending on 
the presence of FMD in the wildlife population, and also the presence of a FMD control program.  
Import regulations help prevent FMDV from being introduced from endemic regions in infected animals or 
contaminated foodstuffs fed to animals. Waste food (swill) fed to swine is a particular concern. Heat-treatment 
can kill FMDV and reduces the risk of an outbreak; however, some countries have completely banned swill 
feeding, due to difficulty in ensuring that adequate heat-treatment protocols are followed. Protocols for the 
inactivation of FMDV in various animal products such as milk products, meat, hides and wool have been 
published by the OIE. Global FMD control programs have recently been established to reduce virus circulation 
and the incidence of this disease. 
Measures taken to control an FMD outbreak include quarantines and movement restrictions, euthanasia of 
affected and exposed animals, and cleaning and disinfection of affected premises, equipment and vehicles. 
Additional actions may include euthanasia of animals at risk of being infected and/or vaccination. Infected 
carcasses must be disposed of safely by incineration, rendering, burial or other techniques. Rodents and other 
vectors may be killed to prevent them from mechanically disseminating the virus. People who have been 
exposed to FMDV may be asked to avoid contact with susceptible animals for a period of time, in addition to 
decontaminating clothing and other fomites. Good biosecurity measures should be practiced on uninfected 
premises to prevent entry of the virus. 
Vaccination may be used to reduce the spread of FMDV or protect specific animals (e.g. those in zoological 
collections) during some outbreaks. The decision to use vaccination is complex, and varies with the scientific, 
economic, political and societal factors specific to the outbreak. Vaccines are also used in endemic regions to 
protect animals from illness. FMDV vaccines only protect animals from the serotype(s) contained in the vaccine. 
For adequate protection, the vaccine strains must also be well matched with the field strain. 
Experimentally, interferon has been evaluated to stop the disease while the immunity elicited by vaccination 
develops. http://www.ars.usda.gov/is/pr/2013/131203.htm.  
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Wildlife transmission may need to be considered in some locations. One important issue is the persistence of 
FMDV in wild African buffalo, which may make eradication unfeasible in some areas. In southern Africa, 
transmission from African buffalo has been controlled by separating wildlife reserves from domesticated 
livestock with fences, and by vaccination of livestock. However, wildlife fencing may not be practical in some 
areas, and there are also some disadvantages to its use. Another issue is the protection of highly susceptible 
wildlife species from FMDV. Vaccination of livestock was reported to decrease outbreaks in some populations, 




There is no specific treatment for FMD, other than supportive care. Treatment is likely to be allowed only in 




In order to reduce the FMD disease burden, the FAO and the OIE developed a 15-year global control strategy in 
2012 (Figure 9).  
Since the global FMD control strategy was brought to light, several initiatives were made to establish an enabling 
environment to make FMD control a feasible option particularly for countries where the disease is most 
prevalent. Progressive control pathway for FMD (PCP-FMD) was developed in 2008 and published in 2011 by 
FAO and EuFMD and became a joint FAO-EuFMD-OIE guiding tool for the national control approach in which 
standard control measures are applied in a step-wise and monitored manner. PCP document: 
http://www.fao.org/ag/againfo/commissions/docs/PCP/PCP-26012011.pdf  
Out of 87 FMD-affected nations, at least 60 are currently engaged at various levels in the implementation of 
PCP-FMD in the quest to reduce or eliminate FMD virus circulation by 2027. Some regions are making progress 
in FMD Control, such as South America and South East Asia. However, still a number of countries in Asia, Middle 
East and Africa are endemic for FMD. 
The PCP includes criteria for describing the FMD risk management of countries that are not-free of FMD. It has 
led to a tool that can be applied to measure (and communicate) country progress within regional roadmaps, and 
aims at starting countries along a pathway of activities from measuring risk to risk management, covering the 
stages before they could apply for recognition of disease freedom. 
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The PCP recognises that differences in risk of infection occur between (and within) infected countries, that 
countries are at different stages in managing the risk of infection.  The PCP applies a risk reduction approach in 
which each Member State is encouraged to develop national risk reduction strategies that are supportive to the 
regional effort. 
The PCP stages are summarized in Figure 10. The ‘Stage Focus’ represents overall objective or aim of the stage, 
and each Stage Focus has a number of ‘key outcomes’ necessary to achieve that aim. Countries are able to 
decide for themselves how far, and how fast, it is appropriate for them to progress along the PCP. The Stage 
Focus therefore does not necessarily assume that a country will progress to the next stage.  In order to be placed 
in a Stage, the country must have achieved all of the key outcomes from the previous Stage, plus have met the 
minimum requirement for inclusion in the current Stage. Completion of a Stage depends on the attainment of a 
specific ‘indicator’ outcome that the country is ready to move to the next Stage. The indicator for each Stage is 
also described in Figure 10.  The PCP approach is not intended to be prescriptive and particularly in the lower 




Figure 9: Global FMD control strategy. FAO & OIE, 2012. (click on figure for the link) 
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Figure 10: Stage progression in the FMD Progression Control Pathway.  Source: PCP-FMD. FAO, EuFMD, 
FAO. 
 
For an effective implementation of the global FMD strategy and to resolve some of the anticipated challenges, 
regional roadmap platforms have been successfully used to assess the progress of FMD control in accordance to 
PCP-FMD guidelines. According to genetic and antigenic analyses, FMD viruses currently circulating have been 
sub-divided into seven regional pools (Figure 2). As distinctive virus strains tend to occur within a defined region, 
regional roadmaps have been established in five of the seven regional virus pools (2-6). The FMD roadmap 
meetings are aimed at sharing information on FMD virus circulation in the region, assessing the progress of each 
country along the Regional Roadmap and working with them on preparing their national control programmes, 
project proposals and submissions to OIE for programme endorsement.  
Link to roadmaps status in Asia: http://www.rr-asia.oie.int/activities/regional-programme/fmd/oiejtf-project-
for-fmd-control-in-asia/  
Figure 11 shows the different PCP stages of countries in Africa in 2014. Figure 12 shows the Global PCP-FMD 
map in 2015.  [Note: Figure 11 has been included, as some African countries are not assessed in Figure 12]. 
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Figure 12: PCP-FMD, Global Map, October 2015.  Source: Status of Global FMD Control Programs. Dr Samia 
Metwally, FAO. Presented at GFRA Scientific meeting, Hanoi 205. Link. 
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Options and strategies for control programs at national, sub-national or regional level 
The AU-IBAR, has developed standard methods and procedures (SMPs) for control of FMD in the Greater Horn 
of Africa, which includes a section in Control, that covers vaccine, vaccine quality control, vaccine use and 
registration, procedure for vaccination, disease control planning, preparedness planning, rapid response plan, 
and recovery plan (pages 19-22 of the following link: http://www.au-
ibar.org/component/jdownloads/finish/76/2118) 
Regional communities in Africa such as the Southern African Development Community (SADC), have also been 
working on FMD control, supporting PCP: http://www.oie.int/doc/ged/D10576.PDF  
At country level, many countries have their own control programs, and different regions or provinces might be 
at different stages. It is not intended to present them here in detail.  Only India and South Africa are mentioned 
as examples.  
 
Control Program in India: 
India has an OIE endorsed official control program, as per OIE resolution May 2015. The districts in which a 




Figure 13: FMD control program in India. Source: Ranjan et al. Understanding FMD viral ecology and 
landscape epidemiology toward control and eradication FMD in India.  GFRA Scientific Meeting, Hanoi, 
2015. 
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Control Program in South Africa: 
South Africa is recognized by the OIE, as having a FMD free zone where vaccination is not practiced. There is an 
infected zone (red in the map – Figure 14 below) which includes mainly the Kruger National Park, a protected 




Figure 14: FMD in South Africa. Source: Scott et al, 2015. Engineering tailor made FMD vaccines for Africa 
with increased thermostability. Presentation at GFRA Scientific Meeting, Hanoi 2015. 
 
Rationale for control 
If money is spent on disease control, the intention is to reduce losses elsewhere by a greater amount. These 
losses may be due to reduced production or restricted market access [4]. To control FMD governments must 
create an environment where population level control costs reflect the benefits experienced by the livestock 
sector and the wider economy. This requires a combination of: 
• Investments in veterinary services, education, research and general infrastructure to develop the animal 
health system – what economists would call fixed costs. 
• Specific programs that cover the costs of FMD control and management – what economists would call variable 
costs.  
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In many countries there is already a fixed cost investment in animal health systems, and adding an FMD control 
program is relatively easy. However, countries that have low level investments in animal health will struggle to 
implement an effective FMD control program. In this situation there needs to be an increase in both the fixed 
and variable costs. The fixed cost element will generate capacity and skills that will benefit the control of other 
diseases and therefore not all costs for this element should be assigned to FMD. 
There are many cost benefit analysis studies of FMD control and eradication.  A summary as compiled by Knight-
Jones and Rushton 2013, is showed in Annex 3.  
In cases of outbreak control, is important to evaluate the different outcomes and costs.  For example, Figure 15 





Figure 15: Comparison UK and Uruguay FMD outbreaks in 2001. Source: Roth, 2014. FMD vaccination: 
Preparedness, availability and limitations.  
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Disease situation and government policies by country:  
Tables 9 and 10 below have been completed with the information received so far from the questionnaires sent 
to the DG and DVS.  This information will be updated and completed once the results from the different 
countries are received.  The list of respondents is included in Annex 4.  
Table 9 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 10 refers to vaccination. 
 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
or within a zone or compartment of that country. 
Table 9: Official status, official programs and treatment for bovine FMD in the countries of interest.  




















Bangladesh Yes Yes, passive and 
targeted 
Yes (limited to 
some districts) 
Yes Yes 
India      
Indonesia      
Myanmar (Burma) Yes Yes, passive Yes No Yes 
Nepal No* Yes, active Yes N/A N/A 
Vietnam Yes Yes, active Yes No Yes 
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Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive but 
active if outbreak 
Yes Yes If animals are sick 
Ethiopia      




Madagascar      
Malawi Yes Yes, passive and 
active 
Yes N/A N/A 
Mali Yes Yes, passive Yes No No 
Mozambique      
Rwanda  Yes Yes, active and 
passive 
Yes No No 
Senegal      
South Africa      
Tanzania  Yes Yes, passive and 
active 
Yes No No 
Uganda Yes Yes Yes Yes (secondary 
infections) 
Yes 
Zambia Yes Yes, active Yes No No 
 
Data has been entered as to reflect information as provided by the respondents.  
 
*: It is surprising that FMD is not notifiable in Nepal, having an official surveillance and an official control program in place. 
It might be a mistake in the form, but has not been confirmed.  
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Table 10: Vaccination for bovine FMD in the countries of interest.  
















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh No Combination: 
government subsidy, 




Cattle and buffalo 
India     
Indonesia     
Myanmar (Burma) No Government Official Cattle, sheep, goats, pigs 
Nepal No Combination Both Cattle, buffalo, sheep and 
goats 
Vietnam Yes Government and 
farmers 
Both Cattle, buffaloes 
AFRICA 
Burkina Faso     
Côte d'Ivoire (Ivory 
Coast)  
No Farmer Private Cattle, sheep and goats 
Ethiopia     
Kenya As per national 
strategy 
Combination Both Cattle 
Madagascar     
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Malawi Yes Government Official Cattle 
Mali No Combination Official Cattle 
Mozambique     
Rwanda Yes Government Official Cattle 
Senegal     
South Africa     
Tanzania  No Combination Both Cattle 
Uganda No 90% Government Official (<90%) Cattle 
Zambia Yes Government Official Cattle 
 
Data has been entered as to reflect information as provided by the respondents.   
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According the OIE Terrestrial Manual, traditional FMD vaccines may be defined as a fixed formulation 
containing defined amounts (limits) of one or more chemically inactivated cell-culture-derived preparations of a 
seed virus strain blended with a suitable adjuvant/s and excipients.  Antigen banks may be defined as stockpiles 
of antigen components, registered or licensed according to the finished vaccine, and which can be stored under 
ultra-low temperatures for a very long time for subsequent formulation into vaccine as and when required. 
FMD vaccines may be classified as either ‘standard’ or ‘higher’ potency vaccines. Standard potency vaccines are 
formulated to contain sufficient antigen and appropriate adjuvant to ensure that they meet the minimum 
potency level required (recommended as 3 PD50 [50% protective dose]) for the duration of the shelf life claimed 
by the manufacturer. This kind of vaccine is usually suitable for use in routine vaccination campaigns.  For 
vaccination in naïve populations to control FMD outbreaks, higher potency vaccines (e.g.> 6 PD50 for the 
duration of the shelf life claimed by the manufacturer) are recommended for their wider spectrum of immunity 
as well as their rapid onset of protection. 
Conventional live attenuated vaccine types for FMD are not acceptable due to the danger of reversion to 
virulence and their use would prevent the detection of infection in vaccinated animals. 
FMD vaccines can be monovalent or polyvalent in relation to the serotype of antigen.  Because of the presence 
of multiple serotypes of the virus, it is common practice to prepare vaccines from two or more different virus 
serotypes. In certain areas, it may be advisable to include more than one virus strain per serotype to ensure 
broad antigenic coverage against prevailing viruses.  
Currently, a number of commercially manufactured vaccines are available of differing strain composition, 
antigenic content, adjuvant formulation and cost. All are produced using inactivated antigens. Vaccine is 
available as fully formulated and tested product or, more usually in emergency situations, it can be freshly 
formulated from concentrated, inactivated antigen(s) stored at low temperature in vaccine banks maintained by 
commercial manufacturers or by national and international authorities. Inactivated FMD vaccines are unable to 
induce sterile immunity, and viral replication may happen in the epithelial surface of vaccinated animals, 
resulting in a carrier state of FMDV [8]. Although no evidence showed that the vaccinated carrier cattle could 
transmit the virus.  
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The FMD vaccines available from commercial sources have remained virtually unchanged for several decades 
and there has been less investment in research and development by manufacturers than was formerly the case. 
FMD vaccine is a high-cost product in particular since it must be produced within biosecure facilities which are 
expensive to establish and maintain, particularly in developing countries. 
 
Method of manufacture – OIE Terrestrial Manual 
The recommended method of virus propagation for antigen production is the growth of FMDV in large-scale 
suspension cultures or monolayers of an established cell line (BHK).  When the virus is expected to reach the 
maximum yield, the culture is clarified, and the virus is subsequently inactivated by addition of an inactivant 
usually binary ethyleneimine (BEI). After inactivation, any residual BEI can be removed or neutralized.  The 
inactivated virus may be concentrated/purified by procedures such as ultrafiltration, polyethylene glycol 
precipitation or polyethylene oxide adsorption.  Concentrated inactivated virus may be purified further by 
procedures such as chromatography.  These concentrated antigens can be formulated into vaccines or stored at 
low temperatures for many years.  
Conventional FMD vaccines are usually formulated as oil adjuvanted or aqueous vaccines.  Oil-adjuvanted 
vaccines are usually formulated as water-in-oil emulsion. Double emulsions may also be used.  The aqueous 
vaccine is prepared by adsorbing the virus on to aluminium hydroxide gel.  The final blend of the vaccine may 
include other components such as antifoam, phenol red dye, lactalbumin hydrolysate, tryptose phosphate broth, 
amino acids, vitamins, buffers, salts and other substances.  An adjuvant, such as saponins, and preservatives may 
also be incorporated.  
For vaccines destined for cattle, both aluminium hydroxide saponin adjuvanted and oil adjuvanted vaccines are 
used. Oil adjuvanted vaccines are at least as effective as aluminum hydroxide vaccines in ruminants, but 
whether they induce better immunity has been debated. Double oil-emulsion vaccines are thought to provide a 
stronger and longer antibody response than water-in-oil single emulsion vaccines. Vaccines with oil adjuvants 
are reported to have a better shelf life. The aluminum hydroxide-saponin formulated vaccines have the 
advantage of being easier to produce, however they can cause granulomas at the inoculation site and are not 
effective in pigs [9]. For use in swine, double oil emulsions are preferred due to their efficacy. Aluminum 
hydroxide vaccines are also less potent per microgram of antigen, and produce a shorter duration of immunity 
[10]. 
The shelf life of conventional formulated FMD vaccines is usually 1-2 years at 4°C (range 2-8°C). Some 
emergency FMD vaccines may be less stable. This effect has been reported for some vaccines but not for others, 
and might be caused by proteases from the culture harvest and/or the type of formulation [1].  
Strain-related differences may affect vaccine manufacture and storage. When used in a vaccine, serotype O is 
less immunogenic than other serotypes, and requires a higher antigen payload. The payload of each antigen 
generally varies from 1 to 10 μg, depending on the antigenicity of the strain. In case of serotype O and SATs, 
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more antigen is required compared with serotype A, Asia I and C, in order to achieve an equivalent potency. This 
type of variation in potency may be attributed to the unequal stability of antigen in different serotypes of FMDV. 
The 146S particles have been considered as an immunogenic component of FMD vaccines and any degradation 
of 146S particles may reduce the potency of the vaccine [11].  SAT-1, SAT-2, and SAT-3 viruses are less stable than 
other serotypes, and SAT-2 and SAT-3 viruses can dissociate under mildly acid conditions. FMDV capsids 
comprise twelve-pentameric protein assemblies held together by tenuous electrostatic and hydrophobic 
interactions. Disassembly and the release of the RNA genome can be triggered by pH <7 or temperature >30°C. 
The serotypes with a highly significant impact in East Africa e.g. O and SAT2, are least stable, and current 
vaccines, produced by chemical inactivation of live virus, further destabilize the capsid. Capsid integrity is 
essential since the presentation of multiple copies of epitopes elicits protective immune responses. To ensure 
that vaccines containing the SAT serotypes are potent and remain so during storage, extra quality assurance 
steps must be taken.  Controls for FMD vaccines, can be seen in Figure 16.  
 
Vaccine matching tests  
Appropriate vaccine strain selection is an important element in the control of FMD (Figure 16). Vaccination 
against one serotype of FMDV does not cross-protect against other serotypes and may also fail to protect fully 
or at all against other strains of the same serotype.  The two important determinants that will affect the efficacy 
of a vaccine and determine whether it will protect or not are:  
1) the ability of the vaccine strain to elicit antibodies that will cross-react and protect against the field or 
outbreak virus in question (defined as the vaccine or antigenic match), and 
2) the potency of the vaccine to elicit a strong and long-lasting immune response.  Higher potency vaccines 
result in a faster onset of immunity and less virus shedding. They are also thought to provide better protection 
against heterologous strains of FMDV within the same serotype, although this might vary with the strain. 
Boosters are an alternative to increase vaccine efficacy, and can also improve the breadth of antigenic cover by 
increasing the amount of cross-reactive antibodies. However, immunity develops more slowly than if a single 
dose of a highly potent vaccine is used, and protection against heterologous strains is not expected to last as 
long as with a well-matched vaccine. The quality and quantity of the antigen in the vaccine as well as the 
formulation of the vaccines and inclusion of immune-stimulating adjuvants are all factors that will influence and 
contribute to the overall potency of the vaccine. Formulating vaccines with higher potency may result in fewer 
doses if the antigen amount is limited, and it may be more expensive. 
The most direct and reliable method to measure cross-protection is to vaccinate relevant target species and 
then to challenge them by exposure to the virus isolate against which protection is required. This will take 
account of both potency and cross-reactivity. However, such an approach requires the use of live FMDV and 
appropriate biosecurity procedures and practices must be used. This procedure is slow and expensive and 
requires specific expertise that is best available in OIE Reference laboratories. The use of animals for such 
studies should be avoided where possible by the use of in vitro alternatives.   
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A variety of in vitro serological methods can be used to quantify antigenic differences between FMDV strains and 
thereby estimate the likely cross-protection between a vaccine strain and a field isolate. Genetic 
characterization and antigenic profiling can also reveal the emergence of new strains for which vaccine matching 
may be required and, conversely, may indicate that an isolate is similar to one for which vaccine matching 
information is already available.  
The OIE recommends that the two dimensional virus neutralization test (VNT) be used. Matching by ELISA has 
also been described; however, the OIE currently recommends its use only for screening. The ‘r’ value indicates 
the closeness of the match in serological tests, with r1 > 0.3 in the VNT suggesting that a potent vaccine is likely 
to be protective. Matching by serological tests cannot account for differences in vaccine potency. If r1 suggests 
that a vaccine strain does not provide a sufficient match for the field virus, a heterologous cross-protection 
challenge test can be conducted. Alternatives are to match the field isolate against other vaccine strains, or 
adapt a field virus to produce a new vaccine. 
However, interpretation of the VNT is plagued by limitations, including the uncertainty as to how well the in 
vitro matching data actually correlates to in vivo cross-protection, the impact of vaccine potency on protection, 
and the availability of reference reagents. Furthermore, the use of r1-values to estimate cross-protection relies 
on having sufficient repeated measures to overcome the inherent variability of the neutralization titers [7]. In a 
recent study with SAT1 viruses, it was found that a number of factors impair reproducibility in one-way 
relationships, such as the operator, batch variability of reagents, day-to-day variation in the cells, and variation 
in individual cattle sera. It is also known that measuring the titer ratio to a known control is not sufficient to 
eliminate the inter-experiment variability, highlighting the necessity for time-consuming duplicate tests to be 
undertaken on separate and independent occasions to compensate for day-to-day variations. A novel way to 
quantify and visualize antigenic relationships is antigenic cartography. However, the combination of genetic 
sequencing and antigenic profiling of the outbreak virus are still useful methods to identify newly emerging or 
re-emerging virus strains and whether available vaccine strains are likely to provide protection against the 
outbreak virus or not. Alternatively, serological cross-reactivity can be estimated using a liquid-phase blocking 
ELISA, and more recently a new approach using linear mixed-effect models to estimate antigenic matching has 
also been described [7].   Simple antibody recognition measures do not always correctly predict the ability of a 
vaccine to protect against an outbreak virus. The antibody isotype, the avidity of the antibody to the virus in 
question, and the type of immune response elicited are also important factors to consider. In a recent study 
comparing the accuracy of traditional and novel serological assays to predict cross-protection, it was found that 
the use of VNT titers and r1-values are inaccurate indicators of protection. However, when the VNT titers were 
combined with the IgG1 titer, a more accurate estimate of FMD vaccine protection against the heterologous 
virus for serotype A was achieved. To date, the correlation of in-parallel serological data, like VNT and IgG1, 
IgG1/IgG2, or antibody avidity in cross-protection in the case of SAT viruses is unknown [7]. 
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INTA in Argentina, developed and successfully evaluated two high-throughput ELISA techniques, avidity and IgG 
subtype ELISA to indirectly assess heterologous protection [12]. In later studies [13], when using traditional and 
novel serology tests, they concluded that due to the sensitivity of individual tests, two or more tests should be 
used in combination to produce an accurate estimation of protection. INTA has developed now a single dilution 
avidity ELISA for buffaloes’ serum, that matches VNT results more accurately than LPB-ELISA which hasn’t been 
launched yet (see Section 7, Note 4).  
Basic capability to undertake vaccine matching tests on a routine basis in diagnostic laboratories in African 
countries is severely limited, and therefore current advice regarding the selection of the best vaccine to be used 
in these settings is normally provided by regional (ARC-Onderstepoort Veterinary Institute, South Africa; 
Botswana Veterinary Institute, Botswana) and international reference centers.  The OIE/FAO FMD Reference 
Laboratory Network reports over the last five years have revealed a gap in the vaccine strains available to match 
against circulating SAT1 and especially SAT2 viruses. The urgent requirement for the development of new SAT 
vaccine strains with good immunogenicity for use in Africa was also highlighted at the recent Global FMD 
Research Alliance congress (Arusha, Tanzania in October 2013). For the African continent (FMD endemic pools 4, 
5, and 6), at least five vaccine strains are available for SAT1, and seven vaccine strains are described for SAT2 
viruses. However, not all these vaccine strains are of recent derivation or are currently used in production, and it 
is therefore imperative that outbreak samples are properly matched to the vaccine strains that are available for 




Figure 16: Controlling FMD vaccines.  Source: Capozzo, 2012. Indirect parameters related to vaccine efficacy 
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Vaccine from outbreak strain 
If a new vaccine must be prepared from an outbreak strain (either because no reasonably well-matched vaccine 
strain is available, or to optimize vaccine efficacy), the field virus must first be adapted to culture and suspension 
culture to produce enough antigen. While many new vaccines have been produced successfully, some field 
strains do not grow well in culture, and the quality or number of field strains from an outbreak might be 
inadequate. In addition, the adaptation process is time-consuming, and has the potential to result in antigenic 
changes during adaptation and in vitro growth. 
An experimental approach, which might mitigate some of these difficulties, involves the development of new 
vaccine strains by modifying cDNA clones of existing strains. In a study published in 2013, a vaccine was 
developed for a serotype A virus that does not grow well in culture, by substituting the FMDV capsid coding 
region into the cDNA clone of a serotype O vaccine strain [14]. In a similar experiment, partial replacements of 
genetic material were made between field and vaccine strains of SAT viruses [15] . Another group reported 
making genetic modifications to an infectious cDNA clone of a serotype O vaccine strain, to provide broader 
protection against three related field viruses [16]. If the adaptation of a field strain to culture is successful, the 
lead time for vaccine preparation is 1 to 6 months, depending on how readily the strain grows in vitro, its yield 
and immunogenicity, and the tests that must be conducted. 
 
Vaccines for SAT types for use in Africa 
SAT vaccines are a particular case. Vaccination in Africa is complicated by the fact that not only are the 3 SAT 
serotypes of FMDV prevalent in most southern African buffalo populations, but also by considerable 
geographically-specific intratypic variation (topotypes) among these viruses (Annex 1). The SAT1 and SAT2 
viruses display greater antigenic variation compared with the Euro-Asian serotypes. The consequence of this 
genetic variation is for example, that a SAT2 vaccine produced from a South Africa virus isolate will not 
necessary provide protection against a SAT2 outbreak in Kenya and certainly not a SAT2 outbreak in West Africa 
although it is able to elicit protective immune responses against the local circulating viruses. The diversity of 
circulating field strains makes the selection of sufficiently cross-protective FMD vaccine a challenge as already 
discussed. Local and regional programs of surveillance to monitor FMDVs circulating in wildlife and livestock are 
a crucial component of vaccine control, to provide vaccine matching data and access to appropriate viral strains.  
On the other hand, vaccines for SAT types present their own difficulties.  It has also been mentioned that SAT1, 
SAT2 and SAT3 viruses are less stable than other serotypes, and SAT2 and SAT3 can dissociate under mildly 
acidic conditions.  The SAT vaccines need greater payload. Studies have been conducted to evaluate different 
adjuvants for SAT vaccines, and a double water-in-oil-in-water adjuvant, ISA206, elicited protective antibody 
responses against SAT2 serotype in cattle. Inactivated vaccines induce short-lived immunity, and it is 
recommended that naïve animals receive two initial vaccinations (a primary and secondary dose) 3–4 weeks 
apart, followed by re-vaccination every 4–6 months to prevent spread of disease within populations. However, 
in the African environment, this may differ for different manufacturers, depending on the potency of the 
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vaccine, and some manufacturers recommend five vaccinations per annum. There is a definite need to assess 
whether different adjuvants may enhance the duration of immunity against SAT antigens. For these reasons 
vaccination campaigns should be performed regularly, based on 1) the epidemiological circumstances and risk of 
disease spread, 2) the value and life expectancy of species, and 3) the economic status of the country. The 
interval between vaccinations is critical to prevent a “window of susceptibility” and where the continuous or 
sporadic presence of virus in carrier animals is present [7]. 
For more on vaccines for SAT types, please see Note 5 on Section 7, and also Section 8.  
 
Recent developments – new licensed vaccines: 
 
1. Replication defective hAd5-vectored FMD vaccine: 
A human adenovirus 5-vectored serotype A24 FMD vaccines has received a conditional license in the USA, but is 
not being manufactured at this time [1]. This vaccine can be produced without the need for high biosecurity 
conditions, and is compatible with DIVA testing. It is made as a ready-to-use vaccine, and initial estimates 
suggest that it can be stored frozen for at least 3 years.  Vectors generated from human adenovirus 5 (hAd5), a 
mild respiratory pathogen of people, use the replication-defective hAd5, a live vector that lacks three regions of 
the adenovirus genome necessary for virus replication. As a result, it cannot produce new adenoviruses except 
in vitro, within cell lines that have been engineered to contain certain complementation functions. When a 
vaccine construct is transfected into such a packaging cell line, the cell generates virus-like particles consisting of 
the DNA vector inside an adenovirus capsid. These particles are able to attach to the cells of a number of animal 
species and become internalized; however, they cannot replicate and infect additional cells.  Once the virus 
particle enters the cell, the vaccine construct is transported to the nucleus and transcribed. The hAd5-vectored 
FMD vaccine construct encodes all of the FMDV capsid proteins, as well as a few NSPs (2A, 3C and sometimes 
2B) necessary to generate these proteins from the viral precursor polyprotein. The result is the expression of 
FMDV capsid proteins in the animal, and their assembly into “empty capsids,” which do not contain infectious 
nucleic acids. The hAd5 vector does not integrate into the host genome, and the expression of vaccine proteins 
is transient. 
Some completed steps include production and characterization of a master seed virus, master cell line 
production and characterization, the establishment of a scalable manufacturing process for vaccine production, 
technology transfer to a USDA-licensed manufacturing facility and the receipt of regulatory approval for an 
outline of production. The company is also developing hAd5-vectored FMD vaccines for other serotypes and 
strains, to follow conditional and full USDA licensing programs.  An entire program for the licensure of 10 
separate single master seeds expressing relevant FMD constructs is under consideration as a 5-6 year program. 
Most research has been conducted with a construct for A24 Cruzeiro. New vaccines can be generated in this 
system by replacing the capsid coding sequence in the hAd5 vaccine construct. Theoretically, this could produce 
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effective vaccines for a variety of FMDV serotypes and strains, including field strains that have not been adapted 
to cell culture. In practice, some of these constructs might be less effective than the A24 Cruzeiro vaccine, at least 
using the original vector. Early experiments with serotype O vaccines (which require higher antigen doses in 
conventional vaccines) did not demonstrate sufficient protection in pigs. An hAd5-vectored O1 Campos vaccine 
provided only partial protection from challenge. Furthermore, pigs vaccinated with a bivalent vaccine (A24 
Cruzeiro and O1 Campos) produced neutralizing antibodies against both serotypes, but the antibody titers were 
much lower than titers induced by either conventional commercial FMD vaccines or a monovalent hAd5-A24 
Cruzeiro vaccine in previous experiments.  
Some concerns about the use of this vaccine, include that immune responses to the adenovirus vector might 
limit the vaccine’s efficacy if there is pre-existing immunity to other hAd5-vectored vaccines, or if multiple doses 
must be given. Several studies have detected antibodies to this vector in cattle and pigs immunized with hAd5-
vectored FMD vaccines. An experiment in pigs indicated that pre-existing immunity might be a concern, when 
the vaccine was given 2 weeks after injecting the vector alone. In cattle, titers to the vector tend to peak 2 
weeks after vaccination, and a second dose ofhAd5-vectored FMD vaccine, given after the titers had declined, 
was able to boost the immune response.  Other concerns include the need for a relatively high dose to induce 
protection, and the cost of the vaccine. However, recent studies have shown that a SC vaccine in the neck could 
reduce the dose, and the adjuvant poly-L-lysine and carboxymethyl cellulose (ICLC) reduced the vaccine dose [17].  
 
2. Commercial FMD synthetic-peptide vaccine: 
Commercial FMD synthetic-peptide vaccines for use in pigs are available in Asia, but little information is 
available, and surprisingly, there are not many references in the literature.  As far as we could find, there are 3 
of this type of vaccine licenced in China.  From Tiankang Biopharmaceutical (licensed in 2010), China animal 
husbandry group (licensed in 2014), and UBI (licensed in 2014).  The first two are based on peptides 2570 + 
7309, while the UBI vaccine is based on peptides 2600 + 2700 + 2800. 
The FMD synthetic-peptide vaccine from UBI for the prevention of pig FMD was developed by UBI Company and 
licensed for use in Taiwan (www.unitedbiomedical.com) and mainland China (since 2007).  The peptide vaccine 
is based on a sequence from the prominent G-H loop of VP1, one of the 4 capsid proteins. The sequence was 
optimized by the inclusion of a cyclic constraint and adjoining sequences, and broader immunogenicity was 
obtained by the incorporation of consensus residues at hypervariable positions. The peptide also included a 
promiscuous T-helper epitope for effective immunogenicity in outbred populations of large animals [18]. The 
composition of the peptide should undertake adjustment according to the pandemic strains of FMDV, when the 
amino acid in the G–H loop domain of a vaccine does not match with circulating FMDV isolate would lead to 
FMD outbreak.  According to UBI, over a billion doses have been sold of the swine vaccine. The advantages of 
the UBI vaccine, as claimed by the manufacturer, can be seen in Table 11:  
http://www.unitedbiomedical.com/animal-health-vaccines.htm, http://www.unitedbiomedical.com/Foot-
and-mouth-vaccine.htm.  
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In pigs, peptide/protein vaccine candidates have been shown to be promising. Unfortunately, these positive 
results in pigs have not been consistently observed in cattle. Also, UBI peptide vaccine tested in cattle showed 
that this vaccine induced low levels of anti-FMDV serum neutralizing antibodies and failed to protect cattle 
against FMDV type O challenge. It is not allowed to be used in cattle in China [17]. 
Table 11: Advantages of the UBITh® FMD synthetic-peptide vaccine.  Source: UBI 
 
Disadvantages associated with current FMD vaccines Key advantages of UBITh® FMD vaccines over 
classical vaccines 
• The virus must be produced in a high 
containment facility to prevent 
contamination of the immediate 
environment  
• The handling of the virus also means the 
imposition of restrictions on the movement 
of the personnel involved  
• The innocuity of the product must be 
ensured. Several cases of the disease have 
been traced to improperly inactivated virus.  
• The product must be inspected at regular 
intervals to insure immune-potency. In some 
countries this can be as frequent as 3 times 
each year. 
• The product must be reformulated regularly 
with current field strains to prevent loss of 
protective efficacy against newly evolved 
antigenic variants.  
• Adverse side effects 
• A single procedure for the rapid production 
and validation of vaccine for newly 
emerging strains  
• Consensus sequence for breadth of cross-
protection wider than the killed vaccines 
• Combinatorial UBITH® sequence for 
coverage of all animals in genetically diverse 
populations  
• Defined antigenic marker vaccine, for clear-
cut distinction of vaccinated from 
unvaccinated animals (VP1 tests) and clear 
differentiation of vaccinated from 
convalescent animals (NS tests).  
• Absolute safety from biohazard risk, both 
during manufacture and use  
• No toxicity or side effects  




According to UBI website, UBI export their FMD vaccines mainly to China, where they have 35% of the market 
share. There are 2 subsidiaries in China. The one called UBI Shanghai (Shen Lian Biotechnology Co, Ltd) has an 
annual production of over 800 million doses.  
Technical information: 
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• Active ingredients:  The vaccine contains at least 25mcg/ml peptides 2600+2700+2800 
• Dose: 1 ml.   
• Route: IM (in the neck) 
• Primary vaccination:  2 vaccinations, 4 weeks apart. 
• Booster: every 6 months.  Repeat every 4-6 months. 
• Presentation: 50 and 100 ml vials.  
• Conservation & shelf life: Between 2 – 8°C for 12 months.  
• Side effects: Some pigs might have fever for several days after vaccination (less than with inactivated 
vaccines) 
• No information available on efficacy, age and onset of immunity 
The vaccines from Tiankang Biopharmaceutical and China animal husbandry group have similar characteristics, 
except for the use of different peptides.  
 
Personal communications from private pig practitioners in China, have informed that they evaluated the vaccine 
3 years ago, and the level of antibodies was very good, however the protection from clinical signs was poor as 
compared with the inactivated vaccines.   
 
Vaccine Banks 
Non-commercial FMD vaccine banks, which can be activated in emergencies, are maintained in some individual 
countries. There are also two multinational cooperative banks: the North American Vaccine Bank (NAFMDVB) 
for the United States, Canada and Mexico, and the European Union Vaccine Bank (EUVB) for the E.U. Non-
commercial vaccine banks usually operate on a relatively small scale, and an individual bank may be able to 
meet only the initial needs during an outbreak. Because some stocks are duplicated in different banks, it might 
be possible to obtain additional vaccine supplies from other countries. In 2006, representatives of FMD vaccine 
banks approved the creation of an international FMD vaccine bank network, to operate under the auspices of 
the OIE. Some of the goals of the network include addressing sudden increases in the demand for vaccine and 
establishing a global vaccine reserve for FMD, as well as harmonizing vaccine and test standardization and 
certification.  
FMD vaccine banks usually store concentrated antigens, which can be kept at ultra-low temperatures for many 
years. In an outbreak, banks can rapidly formulate stored antigens into complete vaccines. Banks are usually 
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able to make either monovalent or polyvalent vaccines that contain oil or aluminum hydroxide/ saponin as the 
adjuvant. It is possible to adjust the potency of the vaccine according to need and to the relatedness of the field 
and vaccine strains. The time between receipt of the order and vaccine delivery has been estimated to be 4 to 
13 days, depending on the distance the antigens and/or vaccine must be shipped, the daily finishing and filling 
capacity of the manufacturer and the availability of flights.  Vaccine banks can store only a limited number of 
serotypes and strains. Vaccine strains held in banks are generally those felt to have the greatest risk of 
introduction, based on the worldwide epidemiological situation. These stocks are under continual review.  
 
Immunity 
Inactivated FMD vaccines are thought to protect animals by inducing humoral immunity, although there is some 
evidence that they may also stimulate some degree of CMI possibly as the result of cross-priming. Inactivated 
FMD vaccines are not thought to result in any mucosal immunity with the possible exception of certain highly 
potent vaccines, given repeatedly [1].  It also appears that animals vaccinated with FMDV do not elicit a 
predominant antibody response against a single antigenic site, but rather utilize a broad repertoire of epitopes 
on the viral capsid [7]. 
 
Main vaccine needs 
There is a need for a vaccine that: 
1- Provides sterile immunity 
2- Has DIVA capabilities 
3- Uses technology that makes easier to match field strains with vaccine strain 
4- Does not required high level of biosecurity for production 
 
Commercial vaccines manufactured in Africa and Asia  
 
The information summarized in Table 12 below, is based on information from The Center for Food Security and 
Public health, Iowa State University (www.cfsph.iastate.edu/vaccines/index.php and Vetvac (www.vetvac.org).   
More details have not been gathered, as another consultant has been commissioned to perform this task.  
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Table 12: Manufacturers of FMD vaccines in Asia and Africa. 
 




















Type O Inactivated OS 99 
Killed  
FMD 
Type O Inactivated (II) OZK93 
Killed  
FMD Type O Inactivated OS99 + 
OZK93 
  
FMD Type O Synthetic Peptide 
Peptides 2570 + 7309 
  
FMD Type O Inactivated Type O   
FMD Type O, Asia 1 Bivalent 
OHMO2 + Asia 1 
  
China Animal 
Husbandry Group  
 
China FMD (Type O) Vaccine,  
OS/99 Strain 




FMD type O vaccine 




India BioFMD-Oil™  




Brilliant Bio Pharma 
Ltd. 
India FUTVAC™  









Raksha Triovac  
(FMD, Hemorrhagic Septicemia, 
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O, A, Asia-1  
Raksha Biovac  
(FMD, Hemorrhagic Septicemia) 




Raksha Ovac  










Brilliant Bio Pharma 
Ltd. 
India FUTVAC (FMD Vaccine, 
Inactivated IP) ’O’ (strain IND 
R2/75), ‘A’ (strain IND 40/2000) 
and ‘Asia1’ (strain IND63/72) 
Killed.  













Aftopor Trivalent A24 Cruzeiro, 






Thailand FMD Vaccine for Pigs 




FMD for Cattle, Sheep, Goats  




MSD  Decivac FMD  
DOE O1 Manisa 
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Egypt Tri-Aphthovac  


















Bivalent Inactivated FMD 




Polyvalent Inactivated FMD Oil 





Institute of Ethiopia 
Ethiopia FMD Vaccine  
A and O serotype 
Killed. Absorbed on 
aluminium 
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FMD Manufacturers in China (2011).  Source: Qiang & Huachun. FMD vaccines and vaccination in China, 
production use and quality.  International conference on scientific developments and technical challenges in the 
progressive control of FMD in South Asia. New Delhi, 2011.  
 
 
Commercial vaccines imported into Africa and Asia 
 
The information summarized in Table 13 is based on the questionnaire sent to the Directors of Veterinary 
Services office and regulators of the countries of interest.  Note that some vaccines might have been imported 
under DVS dispensation, and they are not necessary licensed in the country.  



























O, A & 
Asia-1 
UK 395,000 350,000 400,000 450,000 
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O & A India 111,000 120,000 95,000 175,000 
India        
Indonesia        
Myanmar 
(Burma) 
Af to por OA 
Asia1 
O, A & 
Asia-1 
France1 - 100 9,000 3,000 
Nepal - - - - - - - 
Vietnam2     16,571,720 20,033,500 23,364,440 
AFRICA 
Burkina Faso        
Côte d'Ivoire 
(Ivory Coast) 
- - - - - - - 
Ethiopia        
Kenya - - - - - - - 
Madagascar        
Malawi Trivalent FMD SAT 1, 2 & 
3 
Botswana 10,000 30,000 15,000 - 
Mali Aftovax SAT1, A & 
O 
Botswana 9,000 31,200 15,000 - 
Mozambique        
Rwanda Fotivax A, O, SAT1, 
SAT2 
Kenya 70,000 80,000 100,000 120,000 
Senegal        
South Africa        
Tanzania  - - - - - - - 
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Uganda3 Fotivax O, SAT1, 
SAT2 
Kenya 980,000 400,000 300,000 476,000 
Uganda4 Fotivax O, SAT1, 
SAT2 
Kenya 730,000 683,200 337,000 150,000 
(est) 
Aftovax  Botswana 150,000    
Zambia - - - - - - - 
 
-   Questionnaire received, no information provided.  
1: There are no FMD vaccine manufacturers in France, so this is probably a mistake.  Based on the name of the vaccine 
given is not possible to be sure, but it might be the vaccine from Merial.  
2: Companies with FMD vaccines registered to import into Vietnam (as supplied by the DVS) are: Intervet (Devivac), Zoetis, 
Merial, Lanzhou Veterinary Research Institute, Harbin, China Agricultural Veterinary Biological Science and Technology.   
3: Reply from the National Drug Authority, Uganda. 





Current use:  The only commercial FMD combination available, is Raksha Biovac, a combination of FMD and 
Haemorrhagic septicaemia, produced by India Immunologicals Limited (IIL).  
Desirable combinations:   
• Cattle: Depending on the geography to be used.  
• Small ruminants: Depending on the geography to be used.  
• Pigs: for a vaccine targeted to Asia, the combination with porcine cysticercosis might be a very good 
opportunity to transform a public good (cysticercosis), into private good.  Combination with other 
vaccines like CSF and PPRS might also be of interest for Asia.    
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.  
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 14 below, should be considered a 
proposal, a live document subject to improvements.  
Important note:  The TPP might be different, depending on the purpose of the vaccine. For example, slightly 
different TPPs might be needed for a vaccine for an endemic area, a vaccine for eradication, or a vaccine for 
emergency situations.  
Minimum attributes (current available vaccine) is based on the following information:    
Aftovaxpur SPC:  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/veterinary/002292/WC500147985.pdf (double oil emulsion) 
Fotivax (Kevevapi): http://www.kevevapi.org/index.php/products/item/15-fotivax-tm (Aluminium hydroxide 
and saponin) 
FMD Vaccine (NVI): http://www.nvi.com.et/fmd.html (Aluminium hydroxide gel and saponin) 
Ideal and current attributes have also been included as described in Rodriguez & Gay, 2011 [10]. 
 
  
Foot and Mouth Disease | Monograph 18 






Table 14: Target Product Profile (TPP) FMD – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen 
 
Inactivated FMD virus (varying number 
of strains)  
Immunogen with protective antigens for 
FMDV 
2 Indication for use Active immunization of cattle and 
sheep from 2 months of age and pigs 
from 10 weeks of age against 
FMD to reduce clinical signs. 
Some manufacturers say cattle over 6 
months of age.  
NVI recommends in Ethiopia to 
vaccinate cattle before November and 
January (high risk season) 
For active immunization of cattle, 
buffalo, sheep, goats, pigs, and wildlife 
to prevent infection and transmission 
3 Recommended species 
 
Cattle, sheep, goats and pigs Cattle, buffalo, sheep, goats and pigs. 
Also all susceptible animals, including 
susceptible wildlife. 
4 Recommended dose 
 
Standard vaccines: 3PD50 
High potency vaccines: ≥ 6 PD50 
 
Cattle from 2 months of age: 2 ml 
Sheep from 2 months of age: 2 ml 
Pigs from 10 weeks of age: 2 ml 
 
Some manufacturers indicate 3 ml for 
cattle, but 2 for small ruminants and 
pigs. Other manufacturers 
recommend 4 ml for cattle. 
Same dose for all species (1 or 2 ml) 
5 Pharmaceutical form 
 
Oil: Emulsion for injection (white 
emulsion after shaking) 
Ready to use solution/suspension 




SC or IM (oral might be important for 
wild buffaloes) 
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7 Regimen - primary 
vaccination 
One injection Single lifetime dose 
8 Regimen - booster Every 6 months.  Some manufacturers 
recommend 4 months.  
Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against disease  Protection against infection. Prevents 
development of carrier state. 
10 Recommended age at first 
vaccination 
If used in an emergency situation 
requiring mass vaccination, limited 
data suggests that the vaccine 
can be safely administered to cattle 
and pigs from 3 weeks of age 
From 1-2 months of age, when other 
vaccines are applied.  
11 Onset of immunity 
 
7 days – 4 weeks 
(vaccines with high payload, can 
induce partial protection at 4 days 
post vaccination) 
1 day  
12 Duration of immunity 
 
4-12 months 
(Depending on vaccine formulation 
and species). 
Lifelong immunity 
13 Expected efficacy Reduction of disease severity and 
clinical signs. Does not prevent 
infection.  
To prevent infection                                                  
n and transmission in 100% of the 
animals. No disease after virulent 
challenge. 
14 Expected safety Oil adjuvant: May produce swellings 
(diameter of up to 12 cm) in most 
animals. Normally resolves over 4 
weeks, but may persist for longer in a 
small number of animals. 
It is common to observe a slight 
increase of rectal temperature of up to 
0.7 °C for 4 days postvaccination. 
AlOH: Swelling may occur at the place 
of inoculation and persist for a few 
weeks.  
Can be used during pregnancy. 
No post-vaccinal reactions at any age. 
Safe for pregnant animals at any stage.  
Safe for all sexes at any age.  
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15 Withdrawal period 
 
21-60 days 
Some manufacturers: 0 days. 
Nil for milk and meat 
16 Special requirements for 
animals 
 Vaccinate healthy animals only Vaccinate all animals 
17 Special requirements for 
persons 
Precautions if self-injection with oil 
adjuvanted vaccine 
None 
18 Package size 
 
50, 100 & 300 ml vials Multiple pack size from 5 doses 
19 Price to end user 
 
  
20 Storage condition and 
shelf-life as packaged for 
sale 
2℃-8℃ - 1 year. Varies 
depending on strains (some can 
be as short as 2 months).  
Stable at 30°C for 4 years 
 
21 In-use stability 
 
Should be used immediately  24 hours or greater 
22 Other:  Cross-protection Only within some serotypes Across all 7 serotypes 
23 Other: Requirement for 
high biosecurity 
containment 
Yes, growth of large amounts of 
infectious virus 
No, noninfectious or attenuated 
vaccines virus production platform.  
24 Other: DIVA compatible Requires antigen purification Negative marker engineered into 
vaccine platform 
25 Other: Ability to 
incorporate emerging viral 
strains 
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
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ANNEX 1:  Epidemiological patterns FMD in Africa 
 
Summarised from: Maree et al, 2014. Challenges and prospects for the control of FMD: an African perspective [7]. 
In Africa, the FMDV serotypes are not uniformly distributed, and each serotype results in different 
epidemiological patterns. The cumulative incidence of FMDV serotypes show that six of the seven serotypes of 
FMD (O, A, C, SAT1, SAT2, and SAT3) have occurred in Africa. The distribution of five serotypes and the different 
topotypes are shown in Figures in next page, A-E. Based on the genetic characterization of the virus and 
antigenic relationship of FMDV in Africa, the virus distribution has been divided into three virus pools: namely, 
pool 4 covering East and North Africa, with predominance of serotypes A, O, SAT1, and SAT2; pool 5 restricted to 
West and northern Africa, with serotypes O, A, SAT1, and SAT2; and pool 6 restricted mainly to South Africa, 
with SAT1, SAT2, and SAT3 serotypes (Figure 2 of the document).  
To understand the complexity of FMD epidemiology in Africa and to assist decision making and improve the 
continental control of FMD, it is important to further divide the virus pools into epidemiological clusters. 
Rweyemamu et al proposed eight epidemiological clusters for Africa (Figure F) based on the distribution of 
serotypes and topotypes in different regions in Africa, animal movement patterns, impact of wildlife, and 
farming systems.  The epidemiological clusters for Africa have the following characteristics:  
1. Indian Ocean Island Countries (Madagascar, Mauritius, and Seychelles) are free of FMD, with a recognized 
status of FMD freedom without vaccination. 
2. The South Southern African Development Community (SADC) cluster includes Swaziland, Lesotho, South 
Africa, Botswana, and Namibia, the southern and western part of Zimbabwe, and the southern part of 
Mozambique. The commercial livestock sectors of South SADC countries, with the exception of Zimbabwe 
and Mozambique, are free from FMD and meet the conditions of the OIE for zonal or country freedom from 
FMD without vaccination. Over the last 5 years, the region has suffered from an increasing number of 
outbreaks in cattle, most of which has been caused by SAT2 viruses. The epidemiology of FMD in this region 
is characterized by virus circulation between the African buffalo, and domestic animals, as well as spread 
among domestic animals, without the involvement of wildlife. In some of these countries, there are 
segregated wildlife areas that harbor African buffalo known to be infected, asymptomatically, with FMDV 
serotypes SAT1, SAT2, and SAT3.  
3. The North SADC cluster comprises the northern part of Zimbabwe, Zambia, northern Mozambique, Malawi, 
and southern Tanzania.  The North SADC cluster countries have to deal with at least four serotypes of the 
virus (A, O, SAT1, and SAT2), and maybe even five (SAT3), each with multiple subtypes in the region. Cross-
border spread of the disease is common, and SAT1 and/or SAT2 outbreaks in Mozambique, Malawi, and 
Zambia between 2002 and 2013 were either because of outbreaks spreading from neighboring countries or 
to internal buffalo–cattle contact. Northern Malawi and Northern Zambia are under constant threat of FMD 
spread from southern Tanzania. 
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4. The Angola cluster may also include the western Democratic Republic of Congo (DRC). Very little is known 
about the true incidence of FMD within this cluster, and no official information is available on the isolation 
of FMDV from Angola since 1974. However, an FMD outbreak has been recorded in Angola in 2009, although 
no virus could be isolated. The southern part of Angola forms part of the Kavango-Zambezi TFCA, and it may 
be appropriate to include it within the South SADC cluster. 
5. The East African Community (EAC) cluster is comprised of Tanzania, Uganda, Kenya, Rwanda, and Burundi, 
plus the eastern part of the DRC. In addition to large livestock populations, this cluster has the highest 
concentration of wildlife in the world. The transmission and maintenance of FMD in this region is complex, 
as farming practices, trade, and wildlife contribute to the maintenance and spread of the virus. Farming is 
dominated by agro-pastoral and pastoral communities and is characterized by communal grazing and 
migrations. Eastern DRC is heavily dependent on trade in livestock from Uganda, Tanzania, Rwanda, and 
Burundi. The cluster probably contains several FMD primary endemic foci, and cross-border epidemiological 
events suggest that animal movement plays an important role in virus dissemination. At least four serotypes 
(A, O, SAT1, and SAT2) are endemic in this cluster, with serological evidence for a fifth serotype (C). A sixth 
serotype (SAT3) was isolated in wildlife (African buffalo) in Uganda in 1970, although it has never been 
isolated from livestock in this cluster. SAT3 was also reported in Uganda in 1997 and in the DRC in 2005, but 
was not genotyped. The role of the African buffalo in the maintenance and transmission of FMD serotypes 
(eg, A and O) that occur in this cluster has not been systematically studied. 
6. The Intergovernmental Authority on Development (IGAD) cluster comprises Sudan, South Sudan, Eritrea, 
Ethiopia, Djibouti, Somalia, Northern Kenya, and Northern Uganda. Similar to the EAC cluster, this cluster 
probably harbors major FMD primary endemic foci. Historically, isolates of serotypes A, O, SAT1, and SAT2 
from Sudan and Ethiopia were genetically related to isolates from Uganda, Kenya, and Tanzania, most likely 
as a result of cross-border movement, a situation that has not changed. 
7. The Soudan/Sahel cluster comprises Western Sudan, Niger, Chad, Burkina Faso, Mali, Northern Nigeria, 
Senegal, and Mauritania. The farming system in this ecosystem is predominantly pastoral, characterized by 
long-distance movement of livestock due to either transhumance or trade. This cluster probably also 
contains important FMD primary endemic areas, and at least four serotypes (A, O, SAT1, and SAT2) of the 
virus have been found. Furthermore, it may be an important disease-corridor cluster, linking the IGAD 
cluster with West Africa and probably West Africa with North Africa. Although the epidemiology of FMD in 
the coastal belt countries of West and Central Africa has not been deeply studied, it seems that this cluster 
probably gets infected from the Soudan/Sahel cluster. It could therefore be described as secondary 
endemic. 
8. North Africa/Maghreb cluster countries Morocco, Algeria, and Tunisia have not reported FMD since 1999, 
most likely because of routine preventive vaccination and other measures. Libya and Egypt have sporadic 
FMD, and take routine preventive vaccination. Libya reported a SAT2 outbreak in 2003, probably as a result 
of live animal introductions from neighboring countries to the south, breaching the Sahara barrier. Libya 
experienced another SAT2 outbreak, this time genetically related to isolates from Sudan (2007) and Nigeria 
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(2008). Egypt also reported a SAT2 outbreak in 2012, the first occurrence of this serotype since 1950. Egypt 
also reported African type A viruses in 2006, 2007, 2009, and 2012, as well as ME-SA (Middle East–South 
Asia) types O and A. Yemen reported EA (East Africa)-3 type O in 2007 and 2009. Thus, North African 
countries will remain at risk from the south and east, but across the majority of their territories, and at-risk 
populations should effectively maintain FMD freedom. 
 
Maps of Africa showing the serotypes and topotype distribution.   
Notes: The topotypes are color coded. The epidemiological clustering is indicated. The epidemiological clusters 
shown A-F do not necessarily indicate the borders of the countries.  
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ANNEX 2: Additional data on disease presence and 
incidence 
 
Reports to OIE on FMD: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.  
FMD in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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FMD in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
FMD in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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ANNEX 3: Cost benefit analysis studies of FMD 
control and eradication programs  
Source: Knight-Jones & Rushton, 2013. The economic impacts of FMD – what are they, how big are they and 
where do they occur? Preventive Veterinary Medicine 112 (2013) 161-173. 
 
